Subject Index

A

ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine), salvage of mechlorethamine, vincristine, prednisone, and procarbazine (MOPP)-resistant advanced Hodgkin's disease, 947
Acetazolamide, amelioration of cisplatin-induced nephrotoxicity by the diuretic, in F344 rats, 999
Acivicin, phase II study of, in colorectal carcinoma: a National Cancer Institute of Canada study, 1121
Aclarubicin
-associated QT_c prolongation and ventricular fibrillation, 527
phase I–II study of, in the treatment of acute myeloid leukemia, 881
phase II trial of, in the treatment of acute nonlymphocytic leukemia refractory to treatment with daunorubicin and cytarabine, 1233
AD-32, significance of the low-density lipoprotein receptor pathway for the in vitro accumulation of, incorporated into low-density lipoprotein in normal and leukemic white blood cells, 515
Address Presented at the Dedication of the R. A. Bloch International Cancer Information Center, Bethesda, Maryland, October 2, 1983, 5
Adenocarcinoma *see* Cancer, adenocarcinoma
Adverse effects, animals
amelioration of cisplatin-induced nephrotoxicity by the diuretic acetazolamide in F344 rats, 999
cisplatin-induced vomiting eliminated by ablation of the area postrema in cats, 401
enhancement of cisplatin nephrotoxicity by probenecid, 445
examination of the correlation of first-week mortality with the gastrointestinal syndrome following chemotherapy, 1005
myocardial effects of mitoxantrone and doxorubicin in the mouse and guinea pig, 841
Adverse effects, man
aclarubicin-associated QT_c prolongation and ventricular fibrillation, 527
acute cerebellar toxicity after high-dose cytarabine associated with CNS accumulation of its metabolite, uracil arabinoside, 1309
anaphylactic reactions to diaziquone, 1215
cisplatin-induced autonomic neuropathy, 659
cisplatin in medulloblastoma with extracranial metastasis: a case report, 1307
cyclophosphamide, methotrexate, and 5-FU (CMF)-induced nausea and vomiting: a controlled study with high-dose metoclopramide, 921
differences in effects of immediate and delayed hyperoxia exposure on bleomycin-induced pulmonary injury, 759
dyspnea following vinblastine or vindesine administration in patients receiving mitomycin plus vinca alkaloid combination therapy, 1029
efficacy trial of pipobroman in essential thrombocythemia: a study of 24 patients, 1339
facial burning from cyclophosphamide, 1057
good response of a paraneoplastic neuromyopathy to cyclophosphamide, 787
hepatic toxicity of low doses of mithramycin in hypercalcemia, 1379
hypercalcemic flare with megestrol acetate, 1420
hypersensitivity reactions induced by etoposide, 959
methylprednisolone and chlorpromazine alone or in combination for the control of cisplatin-induced emesis, 1310
pulmonary toxicity associated with spirogermanium, 907
QT interval prolongation and cardiac dysrhythmia in a patient receiving amsacrine, 1043
recurrent acute toxic optic neuropathy secondary to 5-FU, 565
scalp hypothermia is not effective in the prevention of alopecia in patients treated with doxorubicin and cisplatin combinations, 1387
severe leukopenia induced by aminoglutethimide, 1277
subcutaneous reaction due to intra-arterial infusion of anthracycline, 818
susceptibility to motion sickness and the development of anticipatory nausea and vomiting in cancer patients undergoing chemotherapy, 1177
thrombocytopenia after combination therapy with aminoglutethimide and tamoxifen: which drug is to blame?, 1015
venous thrombosis as a side effect of tamoxifen treatment, 887
Aminoglutethimide
evaluation of, in stage D prostate cancer: an assessment of efficacy and toxicity in patients with tumors refractory to hormonal therapy, 719
severe leukopenia induced by, 1277
and tamoxifen, thrombocytopenia after combination therapy with: which drug is to blame?, 1015
Amphotericin B, effects of, with combination chemotherapy on response rates and on survival in non-small cell carcinoma of the lung, 651
Amsacrine
acute electrocardiographic changes induced by, 1169
combined with PALA, teniposide, and zinostatin in small cell lung carcinoma (EST 2579), phase II study of, 1183
cytogenetic effects of, on human lymphocytes in vivo and in vitro, 989
phase II evaluation of, in colorectal, gastric, and pancreatic carcinomas: a Southeastern Cancer Study Group trial, 929
phase II trial of, in children with advanced metastatic neuroblastoma, 1051
phase II trial of, in metastatic or locally recurrent squamous cell carcinoma from head and neck primaries: a Southwest Oncology Group study, 435
phase II trial of, in pancreatic carcinoma: a Southwest Oncology Group study, 1411
phase II trial of, in patients with hepatoma: a Cancer and Leukemia Group B study, 923

QT interval prolongation and cardiac dysrhythmia in a patient receiving, 1043
relationship between the induction of chromosome damage and cytotoxicity for, and congeners, 625
in squamous cell carcinoma of the uterine cervix: a Southwest Oncology Group study, 443
treatment of metastatic ovarian carcinoma with: a Cancer and Leukemia Group B phase II study, 1397
Anguidine, a broad phase II study of the Southeastern Cancer Study Group, 423
Antiemetic therapy, a review of recent studies and a report of a random assignment trial comparing metoclopramide with delta-9-tetrahydrocannabinol, 163
Antitumor antibiotics and low molecular weight immunomodifiers of microbial origin, 137
L-Asparaginase, and dactinomycin in the treatment of relapsed childhood acute lymphoblastic leukemia, 411
Association between malnutrition and caloric intake, emesis, psychological depression, glucose taste, and tumor mass, 873
5-Aza-2′-deoxycytidine
and cytarabine, antileukemic activity of, against intracerebral L1210 murine leukemia, 1483
effects of dose and duration of exposure on, cytotoxicity for L1210 leukemia in vitro, 1475
effects of, in combination with the biochemical modulator thymidine or the immune modulator pyran copolymer on L1210 leukemia-bearing mice, 1255

B

Baker's antifol, and carmustine, in the treatment of primary brain tumors progressive after irradiation and chemotherapy, 431
Biologicals and biological response modifiers: fourth modality of cancer treatment, 221
Bisantrene
an active drug in patients with advanced breast cancer, 357
-induced cytotoxicity, reduced, and protein-associated DNA strand breaks under hypoxic condition, 367
phase II clinical trial of, in advanced refractory small cell lung cancer, 927
phase II trial of, in advanced epidermoid carcinoma of the head and neck, 687
Bladder cancer *see* Cancer, bladder
Bleomycin
active chemotherapy regimen for squamous cell lung cancer, 475
and cisplatin, addition of, to vincristine, carmustine, doxorubicin, and prednisone (VBAP) combination in the treatment of relapsing or resistant multiple myeloma: a Southwest Oncology Group study, 481
combined with cisplatin and vinblastine (CVB) for relapsed disseminated neuroblastoma, 1157
combined with cisplatin and vinblastine (PVB) in the treatment of malignant germ cell tumors of the ovary, 779
combined with cisplatin and vinblastine, response of a hepatocellular carcinoma to, 1419
combined with cisplatin in the treatment of advanced cervical cancer, 891
combined with 5-FU, vincristine, cyclophosphamide, mitomycin, and methotrexate in the treatment of metastatic urinary bladder cancer, 1167
combined with high-dose methotrexate with leucovorin rescue and vinblastine, with or without tamoxifen, in metastatic renal cell carcinoma, 587
combined with methotrexate, doxorubicin, cyclophosphamide, vincristine, and dexamethasone in the treatment of advanced non-Hodgkin's lymphomas other than diffuse histiocytic or undifferentiated histologies, 1343
combined with vinblastine and cisplatin (VBP) followed by dacarbazine and mitolactol in metastatic melanoma, phase II trial of, 1395
combined with vincristine and methotrexate (VBM), multidrug chemotherapy, and radiotherapy in stage III–IV squamous cell carcinoma of the head and neck, 1019
continuous infusion versus intermittent bolus injection of, in a human embryonal testicular cancer xenograft, 799
and doxorubicin in hepatocellular carcinoma, phase II evaluation of: a Southeastern Cancer Study Group trial, 1517
doxorubicin, vinblastine, and dacarbazine (ABVD) salvage of mechlorethamine, vincristine, prednisone, and procarbazine (MOPP)-resistant advanced Hodgkin's disease, 947
-induced pulmonary injury, differences in effects of immediate and delayed hyperoxia exposure on, 759
phase II evaluation of, in patients with advanced epithelial ovarian cancer, 549
Bone cancer *see* Cancer, bone
Bone marrow transplantation, role of, in the treatment of hematologic malignancies and solid tumors: critical review of syngeneic, autologous, and allogeneic transplants, 145
Bowel cancer *see* Cancer, bowel
Brain cancer *see* Cancer, brain
Breast cancer *see* Cancer, breast
Bronchogenic carcinoma *see* Cancer, lung
Burkitt's lymphoma *see* Cancer, lymphoma
Busulfan, high-dose, and cyclophosphamide with syngeneic or autologous bone marrow rescue, preliminary results of, 711

C

Cancer *see also* Leukemia
adenocarcinoma
advanced, etoposide and cisplatin in the treatment of, 671
phase II study of continuous 5-day vinblastine infusion in, 925
bladder
advanced transitional cell, randomized trial of hexamethylmelamine versus 5-FU, doxorubicin, and cyclophosphamide (FAC) in: a Southwest Oncology Group study, 1025
bilharzial, phase II chemotherapy trial of 5-FU, cyclophosphamide, ifosfamide, and vincristine in the treatment of, 419
bilharzial, randomized phase II trial of hexamethylmelamine versus pentamethylmelamine in the treatment of, 793
metastatic urinary, combination chemotherapy with 5-FU, vincristine, bleomycin, cyclophosphamide, mitomycin, and methotrexate in the treatment of, 1167
bone, osteolytic, long-term effects of dichloromethylene diphosphonate in patients with, and coincident primary hyperparathyroidism, 655
bowel, advanced, evaluation of a sequential 5-FU and

hydroxyurea combination in, 1383
brain
glioblastoma multiforme, phase II trial of prednimustine in, 795
malignant glioma, phase II evaluation of vindesine in the treatment of, 807
malignant, perioperative carmustine chemotherapy for, 1505
phase I–II study of diaziquone in the treatment of, 913
primary tumors, carmustine and Baker's antifol in the treatment of, 431
recurrent malignant, PCNU treatment for, 969
recurrent tumors, phase II trial of PCNU in children with, 441
breast
advanced, bisantrene, an active drug in patients with, 357
advanced, effect of prednisolone on hormone profiles during primary endocrine treatment of, 1447
advanced, evaluation of vinblastine administered by 5-day continuous infusion in women with, 803
advanced, mitoxantrone and cyclophosphamide in patients with, 1283
advanced, phase II study of 4′-epi-doxorubicin in, 1285
advanced, phase II study of mitoxantrone in: an Eastern Cooperative Oncology Group pilot study, 1511
advanced, phase II study of sequential methotrexate plus 5-FU in the treatment of, 547
advanced, phase II study of spirogermanium in, 1515
advanced postmenopausal, phase II study of weekly low-dose 4′-epi-doxorubicin in the treatment of, 675
advanced, sequential continuous infusion with doxorubicin and vinblastine: an effective chemotherapy combination for patients with, previously treated with cyclophosphamide, methotrexate, 5-FU, vincristine, and prednisone, 1039
chemotherapy-refractory metastatic, phase II study of mitolactol in, 1499
correlation between estrogen-receptor proteins and response to chemotherapy in patients with, 577
cyclophosphamide, methotrexate, and 5-FU (CMF)-induced nausea and vomiting: a controlled study with high-dose metoclopramide, 921
disseminated estrogen receptor-negative, aggressive doxorubicin-containing regimen (prednisone, methotrexate, 5-FU, doxorubicin, and cyclophosphamide; PM-FAC) in the treatment of, 1017
human, role of receptors in mediating steroid hormone effects in, 265
metastatic, phase II study of spirogermanium in the treatment of, 1197
refractory advanced, tamoxifen and conjugated estrogens (Premarin) followed by sequenced methotrexate and 5-FU, 1421
refractory metastatic, phase I–II study of high-dose mitomycin with autologous bone marrow transplantation in, 805
relationship between estrogen-receptor proteins and response to chemotherapy in, 573
sequential methotrexate and 5-FU in CMFP (cyclophosphamide, methotrexate, 5-FU, and prednisone) therapy for, 877
sequential methotrexate and 5-FU in, resistant to the conventional application of these drugs, 1279
carcinoid, tumor, metastatic, evaluation of combined cyclophosphamide and methotrexate therapy in the treatment of, and the malignant carcinoid syndrome, 665
cervical
activity of mitolactol in the treatment of, 669
advanced, combination chemotherapy with cisplatin and bleomycin in the treatment of, 891
advanced or recurrent nonsquamous, phase II trial of etoposide in the management of: a Gynecologic Oncology Group study, 1513
squamous cell, amsacrine in the treatment of: a Southwest Oncology Group study, 443
colorectal
advanced, phase II study of sequential methotrexate plus 5-FU in the treatment of, 547
advanced, phase II study of vindesine in the treatment of, 555
advanced, phase II trial of 4-demethoxydaunorubicin in the treatment of, 689
advanced, phase II trial of mitolactol in previously treated and untreated patients with: an Illinois Cancer Council trial, 1303
metastatic, 5-FU, mitomycin, vincristine, and methotrexate in the treatment of, 647
metastatic, phase II evaluation of 4′-epi-doxorubicin in patients with, 1507
metastatic, regional intra-arterial mitomycin C infusion in previously treated patients with, and concomitant measurement of serum drug level, 1319
phase II evaluation of amsacrine in: a Southeastern Cancer Study Group trial, 929
phase II study of acivicin in the treatment of: a National Cancer Institute of Canada study, 1121
endometrial, advanced adenocarcinoma, phase II clinical study of tamoxifen in: a Gynecologic Oncology Group study, 809
esophageal
advanced epidermoid, chemotherapy for, with single-agent cisplatin: final report on a Southwest Oncology Group study, 1023
treatment of, with vindesine: an open trial, 783
gastric
advanced, cisplatin, doxorubicin, and 5-FU in combination for, 1273
advanced, phase II trial of cisplatin in, 1497
phase II evaluation of amsacrine in: a Southeastern Cancer Study Group trial, 929
gastrointestinal tract, adenocarcinoma of upper, phase II study of 4-demethoxydaunorubicin in patients with, 1415
germ cell
advanced nonseminomatous, phase II trial of 13-*cis*-retinoic acid in patients with, 1287
of the ovary, malignant, treatment of with cisplatin, vinblastine, and bleomycin (PVB), 779
head and neck
advanced epidermoid, phase II trial of bisantrene in the treatment of, 687
advanced, phase II study of methotrexate with thymidine protection or rescue in, 543
advanced, phase II trial of mitoguazone in the treatment of, 1301
advanced squamous cell, phase II trial of vindesine in the treatment of, 559

locally advanced, combined modality approach in the management of, 591
metastatic or locally recurrent squamous cell, evaluation of gallium nitrate in: a Southwest Oncology Group study, 1047
metastatic or locally recurrent squamous cell, phase II trial of amsacrine in, 435
phase II study of PCNU in the treatment of, 437
recurrent or metastatic squamous cell, doxorubicin and cisplatin in the treatment of, 1163
recurrent, phase II study of prospidin in the treatment of, 915
squamous cell, phase II trial of ICRF-187 in the treatment of, 427
squamous, palliative treatment of, with cisplatin and hydroxyurea, 932
stage III–IV squamous cell, multidrug chemotherapy (vincristine, bleomycin, and methotrexate [VBM]), with radiotherapy in the treatment of, 1019
hepatocellular
doxorubicin (75 mg/m^2) for: clinical and pharmacokinetic results, 487
phase II evaluation of doxorubicin and bleomycin in: a Southeastern Cancer Study Group trial, 1517
response of, to the cisplatin-vinblastine-bleomycin drug regimen, 1419
hepatoma, phase II trial of amsacrine in: a Cancer and Leukemia Group B study, 923
Hodgkin's disease
mechlorethamine, vincristine, prednisone, and procarbazine (MOPP)-resistant advanced, doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) salvage of, 947
phase II trial of PCNU in children with, 441
phase II trial of vinzolidine, an oral vinca alkaloid, in the treatment of, 1399
study of erythrocyte mean corpuscular volume during cytotoxic therapy as a predictive parameter of the risk of secondary leukemia in, 1467
intra-abdominal, with histologically normal ovaries, 931
large bowel, disseminated, phase II study of sequential methotrexate and 5-FU plus mitomycin and leucovorin in patients with: a Northern California Oncology Group study, 983
liver, primary, phase II trial of mitoxantrone in patients with, 1311
lung
adenocarcinoma, phase II trial of vindesine in the treatment of, 557
advanced adenocarcinoma and large cell carcinoma, cyclophosphamide, doxorubicin, and cisplatin compared to methotrexate, doxorubicin, cyclophosphamide, and lomustine in the treatment of: a North Central Cancer Treatment Group study, 493
advanced adenocarcinoma, phase II study of mitomycin, methotrexate, and vincristine combination chemotherapy in, 1299
advanced, phase II study of diaziquone in patients with, 1193
advanced refractory small cell, phase II clinical trial of bisantrene in, 927
advanced squamous cell, etoposide and cisplatin in the treatment of, 671
advanced-stage, non-small cell, trial of vindesine, etoposide, and cisplatin in patients with previously treated, 413
conventional agents in, 566
metastatic, etoposide infusions for treatment of, 897
metastatic non-small cell, chemotherapy for: cyclophosphamide, doxorubicin, and etoposide versus mitomycin and vinblastine (EST 2575, generation IV), 1325
multiple sequential biomarkers in monitoring patients with, 859
non-small cell, cisplatin, cyclophosphamide, vincristine, and doxorubicin in the treatment of, 1159
non-small cell, cisplatin, doxorubicin, cyclophosphamide, lomustine, and vincristine (PACCO) in the treatment of, 771
non-small cell, combination chemotherapy for, with doxorubicin and mitomycin or cisplatin and etoposide, 1079
non-small cell, effects of amphotericin B with combination chemotherapy on response rates and on survival in, 651
non-small cell (EST 2580), phase II study of PALA and PCNU in the treatment of: an Eastern Cooperative Oncology Group study, 1297
non-small cell, phase I–II study of the continuous infusion of doxorubicin in the treatment of, 681
non-small cell, phase II trial of 4-demethoxydaunorubicin in patients with, 563
phase II evaluation of mitoxantrone in patients with: a Southeastern Cancer Study Group trial, 1295
previously treated small cell, phase II trial of etoposide in, 1413
recurrent small cell, treatment of, with vindesine and cisplatin, 791
relapsed small cell, phase II trial of mitoguazone in patients with, 561
small cell (EST 2579), phase II study of PALA, amsacrine, teniposide, and zinostatin in the treatment of, 1183
small cell, evaluation of vindesine in patients with, 1407
small cell, intrahepatic platinum in the treatment of liver metastases from, 447
small cell, phase II study of teniposide in the treatment of, 1289
small cell, phase II study of vindesine, cisplatin, and hexamethylmelamine (VCH) in, 1179
small cell, role of computerized cranial tomography in the staging of, 1375
squamous cell, an active chemotherapy regimen (vinblastine, bleomycin, methotrexate, 5-FU, cisplatin, and leucovorin) in the treatment of, 475
lymphoma
abdominal undifferentiated, surgical resection and limited chemotherapy for, 599
advanced non-Hodgkin's, methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine, and dexamethasone combined for, other than diffuse histiocytic or undifferentiated histologies, 1343
non-Hodgkin's, phase II trial of vinzolidine, an oral vinca alkaloid, in the treatment of, 1399
phase II trial of PALA in the treatment of: an Eastern Cooperative Oncology Group study, 551
recurrent, vindesine, carmustine, doxorubicin, and prednisone (EBAP) in: a Southwest Oncology Group study, 963
refractory Burkitt's, complete remission in, 818
medulloblastoma, cisplatin in, with extracranial metastasis: a case report, 1307

melanoma
advanced malignant, experience with the colony-forming (stem cell) assay of in vitro chemosensitivity in the management of patients with, 1185
advanced malignant, phase II trial of 4′-epi-doxorubicin in the treatment of, 679
disseminated malignant, combination cytotoxic chemotherapy with procarbazine, vincristine, and lomustine (POC) in: 8 years' follow-up, 1211
malignant, blood leakage and melphalan leakage from the perfusion circuit during regional hyperthermic perfusion for malignant melanoma, 867
malignant, mitoxantrone in the treatment of, 903
malignant, phase II study of mitolactol in the treatment of, 1045
malignant, phase II trial of PCNU in, 1049
metastatic, combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in the treatment of, 1403
metastatic, human leukocyte (alpha) interferon in: the American Cancer Society phase II trial, 723
metastatic malignant, multicenter phase II trial with 5-day continuous-infusion vindesine in the treatment of, 1199
metastatic, phase II trial of 4′-epi-doxorubicin in the treatment of, 1509
metastatic, phase II trial of vinblastine, bleomycin, and cisplatin (VBP) followed by dacarbazine and mitolactol in, 1395
myeloma
chemotherapy-resistant multiple, double hemibody irradiation in, 1173
multiple, human leukocyte interferon and intermittent high-dose melphalan-prednisone administration in the treatment of: a randomized clinical trial from the Myeloma Group of Central Sweden, 1331
multiple, therapy for, with alternating non-cross-resistant chemotherapy combinations: heterogeneity of tumor responsiveness, 1439
phase II evaluation of chlorozotocin in the treatment of, 685
refractory multiple, phase II evaluation of chlorozotocin in, 1409
relapsing or resistant multiple, addition of cisplatin and bleomycin to vincristine, carmustine, doxorubicin, and prednisone (VBAP) in the treatment of: a Southwest Oncology Group study, 481
neuroblastoma
advanced metastatic, phase II trial of amsacrine in children with, 1051
relapsed disseminated, cisplatin, vinblastine, and bleomycin (CVB) therapy for, 1157
ovarian
advanced, 4′-epi-doxorubicin in combination with cisplatin in the treatment of, 1391
advanced epithelial, phase II evaluation of bleomycin in the treatment of, 549
metastatic, treatment of, with amsacrine: a Cancer and Leukemia Group B phase II study, 1397
recurrent adenocarcinoma, phase II trial of razoxane in the management of: a Gynecologic Oncology Group study, 439
refractory epithelial, continuous-infusion vinblastine in the treatment of, phase II trial of, 1417
refractory epithelial, phase II trial of intermittent iv homoharringtonine in the treatment of, 1503
refractory, phase II study of teniposide in the treatment of, 815
refractory, phase II trial of 5-FU administered ip to patients with, 1229
stage III–IV adenocarcinomas, cisplatin-MECY (methotrexate-leucovorin rescue plus cyclophosphamide) versus cisplatin-CHAD (cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin) as initial chemotherapy in, 1433
pancreatic
advanced adenocarcinoma, phase II evaluation of metoprine in the treatment of, 1053
phase II evaluation of amsacrine in: a Southeastern Cancer Study Group trial, 929
phase II trial of amsacrine in: a Southwest Oncology Group study, 1411
prostatic
advanced, phase II trial of etoposide in, 1195
combined iridium 192 interstitial and external beam radiation therapy for the treatment of, 1027
stage D, evaluation of aminoglutethimide in: an assessment of efficacy and toxicity in patients with tumors refractory to hormonal therapy, 719
renal, advanced adenocarcinoma, phase II trial of diaziquone in the treatment of, 1055
renal cell
advanced, phase II clinical trial of mitoxantrone in the treatment of: a Southwest Oncology Group study, 919
advanced, phase II trial of PCNU in, 1049
advanced, phase II trial of spirogermanium in: a Cancer and Leukemia Group B study, 1305
metastatic, high-dose methotrexate with leucovorin rescue, vinblastine, and bleomycin with or without tamoxifen in, 587
sarcoma
advanced, high-dose methotrexate with leucovorin rescue in: a Southwest Oncology Group study, 409
advanced mixed mesodermal uterine, doxorubicin and cisplatin in the treatment of, 1389
advanced soft tissue, treatment of, with low-dose methotrexate: a phase II trial by the European Organization for Research on Treatment of Cancer Soft Tissue and Bone Sarcoma Group, 683
Ewing's, management of: role of radiotherapy in local tumor control, 703
local treatment of: radiation therapy versus surgery, 695
metastatic, mitoxantrone in the treatment of, 813
metastatic osteogenic, treatment of patients with: a report from the Childrens Cancer Study Group, 661
osteogenic, acute myelogenous leukemia following radiation therapy and chemotherapy for, 909
soft tissue, prospective randomized trial demonstrating the efficacy of adjuvant chemotherapy in adult patients with, 1067
soft tissue, role of adjuvant chemotherapy in the management of patients with, 1063
testicular
human embryonal, xenograft, continuous infusion versus intermittent bolus injection of bleomycin in, 799
prognostic value of changes in tumor marker concentrations

during treatment of patients with, 1422
thymoma, invasive or metastatic, chemotherapy of: report of 11 cases, 1205
Cancer clinical trials, importance of prognostic factors in, 185
Cancer metastasis, recent concepts of, and their implications for therapy, 193
Cancer pain, advances in the management of, 173
Cancer surgery: a commentary, 31
***Cancer Treatment Reports* 1959–1983: background review and tabular compilation of most cited articles**, 329
Caracemide, inhibition of ribonucleotide reductase by, 1293
Carboplatin, phase I clinical and pharmacologic trial of, daily for 5 days, 1103
Carcinoid cancer *see* Cancer, carcinoid
Carmustine
and Baker's antifol, in the treatment of primary brain tumors progressive after irradiation and chemotherapy, 431
combined with cisplatin, dacarbazine, and tamoxifen in metastatic melanoma, 1403
combined with vincristine, doxorubicin, and prednisone (VBAP), addition of cisplatin and bleomycin to, in the treatment of relapsing or resistant multiple myeloma: a Southwest Oncology Group study, 481
perioperative, chemotherapy for malignant brain tumors, 1505
vindesine, doxorubicin, and prednisone (EBAP) in recurrent lymphomas: a Southwest Oncology Group study, 963
Cell culture studies
abnormal deoxyuridine suppression as a rapid predictor for antimetabolite chemosensitivity: correlation with in vitro tests of growth inhibition, 631
acquisition of multiple drug resistance by CCRF-CEM cells selected for different degrees of resistance to vincristine, 831
chemosensitivity of human tumor clonogenic cells simultaneously assayed in agar diffusion chambers and in a two-layer agar culture system, 615
cyclophosphamide resistance developed in a human melanoma cell line, 1239
cytotoxicity of several chemotherapeutic agents in a human pancreatic cancer cell line (Colo-357), 429
differences in lipid composition of doxorubicin-sensitive and -resistant P388 cells, 637
effect of the interval between exposures to cytarabine on its cytotoxic action on HL-60 myeloid leukemic cells, 1143
experience with the colony-forming (stem cell) assay of in vitro chemosensitivity in the management of patients with advanced malignant melanoma, 1185
murine leukemia L1210 cell lines with different patterns of resistance to platinum coordination complexes, 1189
probenecid inhibition of methotrexate cytotoxicity in mouse L1210 leukemia cells, 521
protection of normal hematopoietic stem cells from the toxicity of purine base analogs: in vivo application, 1153
significance of the low-density lipoprotein receptor pathway for the in vitro accumulation of AD-32 incorporated into low-density lipoprotein in normal and leukemic white blood cells, 515
use of an in vitro technique to detect mutations induced by antineoplastic drugs in mouse germ cells, 855
Cell differentiation, induced, in cancer therapy, 199
Cervical cancer *see* Cancer, cervical
Chloroplatinic acid, and cisplatin, characteristics of inhibition of human renal adenosine triphosphatases by, 1135
Chlorozotocin
phase II evaluation of, in patients with myeloma, 685
phase II evaluation of, in refractory multiple myeloma, 1409
Chlorpromazine, and methylprednisolone alone or in combination for the control of cisplatin-induced emesis, 1310
Cisplatin
active chemotherapy regimen for squamous cell lung cancer, 475
and bleomycin, addition of, to vincristine, carmustine, doxorubicin, and prednisone (VBAP) combination in the treatment of relapsing or resistant multiple myeloma: a Southwest Oncology Group study, 481
and chloroplatinic acid, characteristics of inhibition of human renal adenosine triphosphatases by, 1135
combination chemotherapy, immediate termination of intractable vomiting induced by, using an intensive five-drug (metoclopramide, diphenhydramine, dexamethasone, diazepam, and thiethylperazine) antiemetic regimen, 1493
combined with bleomycin in the treatment of advanced cervical cancer, 891
combined with carmustine, dacarbazine, and tamoxifen in metastatic melanoma, 1403
combined with cyclophosphamide and doxorubicin versus methotrexate, doxorubicin, cyclophosphamide, and lomustine in the treatment of advanced adenocarcinoma-large cell carcinoma of the lung: a North Central Cancer Treatment Group study, 493
combined with cyclophosphamide, vincristine, and doxorubicin in the treatment of non-small cell lung cancer, 1159
combined with doxorubicin and 5-FU in the treatment of advanced gastric cancer, 1273
combined with doxorubicin, cyclophosphamide, lomustine, and vincristine (PACCO) in the treatment of non-small cell bronchogenic carcinoma, 771
combined with 4′-epi-doxorubicin in the treatment of advanced ovarian cancer, 1391
combined with etoposide in the treatment of advanced adenocarcinoma and squamous cell carcinoma of the lung, 671
combined with hydroxyurea, palliative treatment of head and neck squamous cancer, 932
combined with vinblastine and bleomycin (CVB) for relapsed disseminated neuroblastoma, 1157
combined with vinblastine and bleomycin (PVB) in the treatment of malignant germ cell tumors of the ovary, 779
combined with vinblastine and bleomycin, response of a hepatocellular carcinoma to, 1419
combined with vinblastine and bleomycin (VBP) followed by dacarbazine and mitolactol in metastatic melanoma, phase II trial of, 1395
combined with vindesine and etoposide in patients with previously treated, advanced-stage, non-small cell lung cancer, 413
combined with vindesine and hexamethylmelamine (VCH) in the treatment of small cell carcinoma of the lung, phase II study of, 1179
and cytarabine, phase I clinical evaluation of, in patients with advanced cancer, 1097
and doxorubicin combinations, scalp hypothermia is not effective in the prevention of alopecia in patients treated with, 1387

and doxorubicin in the treatment of advanced mixed mesodermal uterine sarcoma, 1389
and doxorubicin in the treatment of recurrent or metastatic squamous cell carcinoma of the head and neck, 1163
and etoposide or doxorubicin and mitomycin, combination chemotherapy for non-small cell lung cancer, 1079
high-dose ip, and iv sodium thiosulfate, its antidote, "two-route chemotherapy" using, for peritoneally disseminated cancer in mice, 1367
-induced autonomic neuropathy, 659
-induced emesis, methylprednisolone and chlorpromazine alone or in combination for the control of, 1310
-induced nephrotoxicity, amelioration of, by the diuretic acetazolamide in F344 rats, 999
-induced vomiting eliminated by ablation of the area postrema in cats, 401
intrahepatic, in the treatment of liver metastases from small cell lung cancer, 447
mechanisms for the renal secretion of, 849
-MECY (methotrexate-leucovorin rescue plus cyclophosphamide) versus cisplatin-CHAD (cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin) as initial chemotherapy in stage III–IV ovarian adenocarcinoma, 1433
in medulloblastoma with extracranial metastasis: a case report, 1307
nephrotoxicity, enhancement of, by probenecid, 445
pharmacokinetics of free and total platinum species after short-term infusion of, 505
phase II trial of, in advanced gastric cancer, 1497
single-agent, chemotherapy for advanced epidermoid carcinoma of the esophagus with: final report on a Southwest Oncology Group study, 1023
and vindesine, treatment of recurrent small cell lung carcinoma with, 791
Clinical Development of Anticancer Agents—A National Cancer Institute Perspective, 77
CMF (cyclophosphamide, methotrexate, and 5-FU), -induced nausea and vomiting: a controlled study with high-dose metoclopramide, 921
CMFP (cyclophosphamide, methotrexate, 5-FU, and prednisone), sequential methotrexate and 5-FU in, in the treatment of breast cancer, 877
Colorectal carcinoma *see* Cancer, colorectal
Commentary on "Clinical Predictivity of Transplantable Tumor Systems in the Selection of New Drugs for Solid Tumors: Rationale for a Three-Stage Strategy," 1317
Contrasting viewpoints on cancer drug development: the Wooldridge and Richardson reports, 339
CVB (cisplatin, vinblastine, and bleomycin) (*see also* **P**/B), for relapsed disseminated neuroblastoma, 1157
Cyclophosphamide
blood levels of alkylating metabolites of, in the mouse after iv or oral administration, 765
combined with cisplatin, doxorubicin, lomustine, and vincristine (PACCO) in the treatment of non-small cell bronchogenic carcinoma, 771
combined with cisplatin, vincristine, and doxorubicin in the treatment of non-small cell lung cancer, 1159
combined with doxorubicin and cisplatin versus methotrexate, doxorubicin, cyclophosphamide, and lomustine in the treatment of advanced adenocarcinoma-large cell carcinoma of the lung: a North Central Cancer Treatment Group study, 493
combined with doxorubicin and etoposide versus mitomycin and vinblastine (EST 2575, generation IV): chemotherapy for metastatic non-small cell bronchogenic carcinoma, 1325
combined with 5-FU and doxorubicin (FAC) versus hexamethylmelamine, randomized trial of, in advanced transitional cell bladder carcinoma: a Southwest Oncology Group study, 1025
combined with 5-FU, vincristine, bleomycin, mitomycin, and methotrexate in the treatment of metastatic urinary bladder cancer, 1167
combined with methotrexate, bleomycin, doxorubicin, vincristine, and dexamethasone in the treatment of advanced non-Hodgkin's lymphomas other than diffuse histiocytic or undifferentiated histologies, 1343
combined with methotrexate, doxorubicin, and lomustine versus cyclophosphamide, doxorubicin, and cisplatin in the treatment of advanced adenocarcinoma-large cell carcinoma of the lung: a North Central Cancer Treatment Group study, 493
combined with methotrexate, 5-FU, and prednisone (CMFP), sequential methotrexate and 5-FU in, in the treatment of breast cancer, 877
combined with prednisone, methotrexate, 5-FU, and doxorubicin (PM-FAC), aggressive doxorubicin-containing regimen, in disseminated estrogen receptor-negative breast cancer, 1017
and cytarabine, alternating pulses of vincristine and prednisone with, versus vincristine and prednisone in the maintenance therapy of acute lymphoblastic leukemia, 581
facial burning from, 1057
good response of a paraneoplastic neuromyopathy to cyclophosphamide, 787
and high-dose busulfan with syngeneic or autologous bone marrow rescue, preliminary results of, 711
methotrexate, and 5-FU (CMF), -induced nausea and vomiting: a controlled study with high-dose metoclopramide, 921
and methotrexate, evaluation of, in the treatment of metastatic carcinoid tumor and the malignant carcinoid syndrome, 665
plus methotrexate-leucovorin rescue (MECY)-cisplatin versus cisplatin-CHAD (cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin) as initial chemotherapy in stage III–IV ovarian adenocarcinoma, 1433
and mitoxantrone in patients with advanced breast cancer, 1283
phase II chemotherapy trial of, in cancer of the urothelial bladder, 419
plasma concentrations of 4-hydroxycyclophosphamide and phosphoramide mustard in patients repeatedly given high doses of, in preparation for bone marrow transplantation, 1247
resistance developed in a human melanoma cell line, 1239
sequential continuous infusion with doxorubicin and vinblastine: an effective chemotherapy combination for patients with advanced breast cancer previously treated with, combined with methotrexate, 5-FU, vincristine, and prednisone, 1039
sinus histiocytosis with massive lymphadenopathy: response

to therapy, 901
Cytarabine
and 5-aza-2′-deoxycytidine, antileukemic activity of, against intracerebral L1210 murine leukemia, 1483
and cisplatin, phase I clinical evaluation of, in patients with advanced cancer, 1097
and cyclophosphamide, alternating pulses of vincristine and prednisone with, versus vincristine and prednisone in the maintenance therapy of acute lymphoblastic leukemia, 581
and daunorubicin, aclarubicin in the treatment of acute nonlymphocytic leukemia refractory to treatment with, phase II trial of, 1233
effect of the interval between exposures to, on its cytotoxic action on HL-60 myeloid leukemic cells, 1143
high-dose, acute cerebellar toxicity after, associated with CNS accumulation of its metabolite, uracil arabinoside, 1309
uptake and toxicity, modulation of, by dipyridamole, 361
and uracil arabinoside, sensitive radioimmunoassay for, in plasma, 1357

D

Dacarbazine
combined with cisplatin, carmustine, and tamoxifen in metastatic melanoma, 1403
doxorubicin, bleomycin, and vinblastine (ABVD) salvage of mechlorethamine, vincristine, prednisone, and procarbazine (MOPP)-resistant advanced Hodgkin's disease, 947
intermittent, phase I trial of, 499
and mitolactol, phase II trial of vinblastine, bleomycin, and cisplatin (VBP) followed by, in metastatic melanoma, 1395
Dactinomycin, and L-asparaginase in the treatment of relapsed childhood acute lymphoblastic leukemia, 411
Daunorubicin, and cytarabine, aclarubicin in the treatment of acute nonlymphocytic leukemia refractory to treatment with, phase II trial of, 1233
Delta-9-tetrahydrocannabinol
antiemetic therapy: a review of recent studies and a report of a random assignment trial compared to metoclopramide, 163
metabolic studies of, in cancer patients, 1427
4-Demethoxydaunorubicin
iv and oral, activity and distribution of, in murine experimental tumors, 739
phase II study of, in patients with adenocarcinoma of the upper gastrointestinal tract, 1415
phase II trial of, in advanced colorectal carcinoma, 689
phase II trial of, in patients with non-small cell lung cancer, 563
Dexamethasone, combined with methotrexate, bleomycin, doxorubicin, cyclophosphamide, and vincristine in the treatment of advanced non-Hodgkin's lymphomas other than diffuse histiocytic or undifferentiated histologies, 1343
Diagnosis of and therapy for solid tumors with radiolabeled antibodies and immune fragments, 317
Diaziquone
anaphylactic reactions to, 1215
phase I–II study of, in brain tumors, 913
phase I study of, 975
phase II study of, in patients with advanced carcinoma of the lung, 1193
phase II trial of, in advanced renal adenocarcinoma, 1055
Dichloromethylene diphosphonate, long-term effects of, in patients with osteolytic bone metastases and coincident primary hyperparathyroidism, 655
Dipyridamole, modulation of cytarabine uptake and toxicity by, 361
Doxorubicin
aggressive doxorubicin-containing regimen (prednisone, methotrexate, 5-FU, doxorubicin, and cyclophosphamide; PM-FAC) in disseminated estrogen receptor-negative breast cancer, 1017
and bleomycin in hepatocellular carcinoma, phase II evaluation of: a Southeastern Cancer Study Group trial, 1517
bleomycin, vinblastine, and dacarbazine (ABVD) salvage of mechlorethamine, vincristine, prednisone, and procarbazine (MOPP)-resistant advanced Hodgkin's disease, 947
and cisplatin combinations, scalp hypothermia is not effective in the prevention of alopecia in patients treated with, 1387
and cisplatin in the treatment of advanced mixed mesodermal uterine sarcoma, 1389
and cisplatin in the treatment of recurrent or metastatic squamous cell carcinoma of the head and neck, 1163
combined with cisplatin and 5-FU in the treatment of advanced gastric cancer, 1273
combined with cisplatin, cyclophosphamide, and vincristine in the treatment of non-small cell lung cancer, 1159
combined with cisplatin, cyclophosphamide, lomustine, and vincristine (PACCO) in the treatment of non-small cell bronchogenic carcinoma, 771
combined with cyclophosphamide and cisplatin versus methotrexate, doxorubicin, cyclophosphamide, and lomustine in the treatment of advanced adenocarcinoma-large cell carcinoma of the lung: a North Central Cancer Treatment Group study, 493
combined with cyclophosphamide and etoposide versus mitomycin and vinblastine (EST 2575, generation IV): chemotherapy for metastatic non-small cell bronchogenic carcinoma, 1325
combined with cyclophosphamide, hexamethylmelamine, and cisplatin (CHAD)-cisplatin versus methotrexate-leucovorin rescue (MECY)-cisplatin as initial chemotherapy in stage III–IV ovarian adenocarcinoma, 1433
combined with 5-FU and cyclophosphamide (FAC) versus hexamethylmelamine, randomized trial of, in advanced transitional cell bladder carcinoma: a Southwest Oncology Group study, 1025
combined with methotrexate, bleomycin, cyclophosphamide, vincristine, and dexamethasone in the treatment of advanced non-Hodgkin's lymphomas other than diffuse histiocytic or undifferentiated histologies, 1343
combined with methotrexate, cyclophosphamide, and lomustine versus cyclophosphamide, doxorubicin, and cisplatin in the treatment of advanced adenocarcinoma-large cell carcinoma of the lung: a North Central Cancer Treatment Group study, 493
combined with vincristine, carmustine, and prednisone (VBAP), addition of cisplatin and bleomycin to, in the treatment of relapsing or resistant multiple myeloma: a Southwest Oncology Group study, 481
differences in lipid composition of, -sensitive and -resistant P388 cells, 637

at a dose of 75 mg/m^2 for hepatocellular carcinoma: clinical and pharmacokinetic results, 487
long persistence of, in human skin after extravasation, 895
and mitomycin or cisplatin and etoposide, combination chemotherapy for non-small cell lung cancer, 1079
and mitoxantrone, myocardial effects of, in the mouse and guinea pig, 841
phase I–II study of the continuous infusion of, in the treatment of non-small cell lung cancer, 681
and razoxane treatment, concomitant, on a weekly schedule, 1035
and vinblastine, sequential continuous infusion with: an effective chemotherapy combination for patients with advanced breast cancer previously treated with cyclophosphamide, methotrexate, 5-FU, vincristine, and prednisone, 1039
vindesine, carmustine, and prednisone (EBAP) in recurrent lymphomas: a Southwest Oncology Group study, 963
Drug resistance in cancer, 87

E

EBAP (vindesine, carmustine, doxorubicin, and prednisone), in recurrent lymphomas: a Southwest Oncology Group study, 963
Endometrial cancer *see* Cancer, endometrial
4′-Epi-doxorubicin
combined with cisplatin in the treatment of advanced ovarian cancer, 1391
phase II evaluation of, in patients with metastatic colorectal carcinoma, 1507
phase II study of, in advanced breast cancer, 1285
phase II trial of, in metastatic melanoma, 1509
phase II trial of, in patients with advanced malignant melanoma, 679
weekly low-dose, phase II study of, in advanced postmenopausal breast cancer, 675
Esophageal cancer *see* Cancer, esophageal
Etoposide
and cisplatin or doxorubicin and mitomycin, combination chemotherapy for non-small cell lung cancer, 1079
combined with cisplatin in the treatment of advanced adenocarcinoma and squamous cell carcinoma of the lung, 671
combined with cyclophosphamide and doxorubicin versus mitomycin and vinblastine (EST 2575, generation IV): chemotherapy for metastatic non-small cell bronchogenic carcinoma, 1325
combined with vindesine and cisplatin in patients with previously treated, advanced-stage, non-small cell lung cancer, 413
high-dose, for refractory malignancies, phase I study of, 1471
hypersensitivity reactions induced by, 959
infusions for treatment of metastatic lung cancer, 897
oral, in gestational trophoblastic disease, 775
phase II trial of, in advanced prostate cancer, 1195
phase II trial of, in previously treated small cell carcinoma of the lung, 1413
phase II trial of, in the management of advanced or recurrent non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study, 1513
warfarin, and vindesine interactions, 817
Ewing's sarcoma *see* Cancer, sarcoma

F

FAC (5-FU, doxorubicin, and cyclophosphamide), randomized trial of hexamethylmelamine versus, in advanced transitional cell bladder carcinoma: a Southwest Oncology Group study, 1025
5-FU
active chemotherapy regimen for squamous cell lung cancer, 475
combined with cisplatin and doxorubicin in the treatment of advanced gastric carcinoma, 1273
combined with cyclophosphamide, methotrexate, and prednisone (CMFP), sequential methotrexate and 5-FU in, in the treatment of breast cancer, 877
combined with doxorubicin and cyclophosphamide (FAC) versus hexamethylmelamine, randomized trial of, in advanced transitional cell bladder carcinoma: a Southwest Oncology Group study, 1025
combined with mitomycin, vincristine, and methotrexate in the treatment of metastatic colorectal carcinoma, 647
combined with PALA and thymidine (biochemically designed combination), phase I evaluation of, 539
combined with prednisone, methotrexate, doxorubicin, and cyclophosphamide (PM-FAC), aggressive doxorubicin-containing regimen, in disseminated estrogen receptor-negative breast cancer, 1017
combined with vincristine, bleomycin, cyclophosphamide, mitomycin, and methotrexate in the treatment of metastatic urinary bladder cancer, 1167
cyclophosphamide, and methotrexate (CMF), -induced nausea and vomiting: a controlled study with high-dose metoclopramide, 921
and hydroxyurea, sequential, evaluation of, in advanced bowel cancer, 1383
plus methotrexate, sequential, in advanced breast and colorectal cancers, phase II study, 547
and methotrexate, sequenced, tamoxifen and conjugated estrogens (Premarin) followed by, in refractory advanced breast cancer, 1421
and methotrexate, sequential, in breast cancer resistant to the conventional application of these drugs, 1279
and methotrexate, sequential, in CMFP (cyclophosphamide, methotrexate, 5-FU, and prednisone) therapy for breast cancer, 877
and PALA, continuous-infusion, phase I study of, 531
phase II chemotherapy trial of, in cancer of the bilharzial bladder, 419
phase II trial of, administered ip to patients with refractory ovarian cancer, 1229
recurrent acute toxic optic neuropathy secondary to, 565
sequential, and methotrexate plus mitomycin and leucovorin in patients with disseminated large bowel cancer, phase II study of: a Northern California Oncology Group study, 983
sequential continuous infusion with doxorubicin and vinblastine: an effective chemotherapy combination for patients with advanced breast cancer previously treated with, combined with cyclophosphamide, 5-FU, vincristine, and prednisone, 1039

G

Gallium nitrate, evaluation of, in metastatic or locally recurrent

squamous cell carcinoma of the head and neck: a Southwest Oncology Group study, 1047
Gastric cancer *see* Cancer, gastric
Gastrointestinal tract cancer *see* Cancer, gastrointestinal tract
Germ cell cancer *see* Cancer, germ cell
Glioblastoma multiforme *see* Cancer, brain
Glioma *see* Cancer, brain

H

Head and neck cancer *see* Cancer, head and neck
Hepatocellular cancer *see* Cancer, hepatocellular
Hepatoma *see* Cancer, hepatoma
Hexamethylmelamine
combined with cyclophosphamide, doxorubicin, and cisplatin (CHAD)-cisplatin versus methotrexate-leucovorin rescue (MECY)-cisplatin as initial chemotherapy in stage III-IV ovarian adenocarcinoma, 1433
combined with vindesine and cisplatin (VCH) in the treatment of small cell carcinoma of the lung, phase II study of, 1179
versus 5-FU, doxorubicin, and cyclophosphamide (FAC), randomized trial of, in advanced transitional cell bladder carcinoma: a Southwest Oncology Group study, 1025
versus pentamethylmelamine, phase II trial of, in the treatment of carcinoma of the bilharzial bladder, 793
Hodgkin's disease *see* Cancer, Hodgkin's disease
Homoharringtonine
intermittent iv, phase II trial of, in the treatment of refractory epithelial carcinoma of the ovary, 1503
phase I clinical investigation of, 1085
Human tumor colony assay and chemosensitivity testing, 117
4-Hydroxycyclophosphamide, and phosphoramide mustard, plasma concentrations of, in patients repeatedly given high doses of cyclophosphamide in preparation for bone marrow transplantation, 1247
Hydroxyurea
combined with cisplatin, palliative treatment of head and neck squamous cancer, 932
and 5-FU, sequential, evaluation of, in advanced bowel cancer, 1383
Hyperparathyroidism, primary, long-term effects of dichloromethylene diphosphonate in patients with coincident osteolytic bone metastasis, 655
Hyperthermia, as a clinical treatment modality, 309

I

ICRF-187, phase II trial of, in squamous cell carcinoma of the head and neck, 427
Ifosfamide, phase II chemotherapy trial of, in cancer of the bilharzial bladder, 419
Immunocytoma, resistant, nonaggressive combination chemotherapy for, 1033
Immunotherapy
adoptive, of cancer: accomplishments and prospects, 233
phase I study of, by live *Brucella abortus* (strain 19 BA) in cancer patients, 417
tumor, current condition of prognosis of: a second opinion, 207
Interferon
human leukocyte (alpha), in metastatic malignant melanoma: the American Cancer Society phase II trial, 723
human leukocyte, and intermittent high-dose melphalan-prednisone administration in the treatment of multiple myeloma: a randomized clinical trial from the Myeloma Group of Central Sweden, 1331
weekly high-dose human lymphoblastoid, phase I study of, 1093
Intra-abdominal cancer *see* Cancer, intra-abdominal
Intramural Therapeutic Research at the National Cancer Institute, Department of Medicine: 1955–1965, 21

L

Large bowel cancer *see* Cancer, large bowel
Leucovorin
active chemotherapy regimen for squamous cell lung cancer, 475
rescue, high-dose methotrexate with, plus vincristine in advanced sarcoma: a Southwest Oncology Group study, 409
rescue-methotrexate plus cyclophosphamide (MECY)-cisplatin versis cisplatin-CHAD (cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin) as initial chemotherapy in stage III-IV ovarian adenocarcinoma, 1433
sequential, and 5-FU plus methotrexate and 5-FU in patients with disseminated large bowel cancer, phase II study of: a Northern California Oncology Group study, 983
Leukemia
acute
improved survival among children with, diagnosed in the 1970s, 953
lymphoblastic, alternating pulses of vincristine and prednisone with cytarabine and cyclophosphamide versus vincristine and prednisone in the maintenance therapy of, 581
myelogenous, following radiation therapy and chemotherapy for osteogenic sarcoma, 909
myeloid, phase I-II study of aclarubicin in the treatment of, 881
nonlymphocytic, aclarubicin in the treatment of, refractory to treatment with daunorubicin and cytarabine, phase II trial of, 1233
nonlymphocytic, contrasting benefits of two maintenance programs following identical induction in children with: a report from the Childrens Cancer Study Group, 1269
refractory adult, phase I-II trial of anthracenedicarboxaldehyde in, 535
relapsed childhood lymphoblastic, L-asparaginase and dactinomycin in the treatment of, 411
use of decline in D-xylose absorption to predict infection following intensive chemotherapy in the treatment of, 1489
chronic myelogenous, treatment of myeloid blastic crisis of, 1351
Liposomes, as drug carriers in cancer therapy, 127
Liver cancer *see* Cancer, liver
L1210 leukemia *see* Tumor systems, animals
Lomustine
combined with cisplatin, doxorubicin, cyclophosphamide, and vincristine (PACCO) in the treatment of non-small cell bronchogenic carcinoma, 771

combined with methotrexate, doxorubicin, and cyclophosphamide versus cyclophosphamide, doxorubicin, and cisplatin in the treatment of advanced adenocarcinoma-large cell carcinoma of the lung: a North Central Cancer Treatment Group study, 493
combined with procarbazine and vincristine (POC) in the treatment of disseminated malignant melanoma: 8 years' follow-up, 1211
Lung cancer *see* Cancer, lung
Lymphoma *see* Cancer, lymphoma

M

Mechlorethamine, vincristine, prednisone, and procarbazine (MOPP)-resistant advanced Hodgkin's disease, doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) salvage of, 947
Medulloblastoma *see* Cancer, medulloblastoma
Megestrol acetate, hypercalcemic flare with, 1420
Melanoma *see* Cancer, melanoma
Melphalan
and blood leakage, from the perfusion circuit during regional hyperthermic perfusion for malignant melanoma, 867
high-dose, with autologous bone marrow rescue for the treatment of advanced adult solid tumors, 471
and prednisone, intermittent high-dose, and human leukocyte interferon administration in the treatment of multiple myeloma: a randomized clinical trial from the Myeloma Group of Central Sweden, 1331
Methotrexate
active chemotherapy regimen for squamous cell lung cancer, 475
combined with bleomycin, doxorubicin, cyclophosphamide, vincristine, and dexamethasone in the treatment of advanced non-Hodgkin's lymphomas other than diffuse histiocytic or undifferentiated histologies, 1343
combined with cyclophosphamide, 5-FU, and prednisone (CMFP), sequential methotrexate and 5-FU in, in the treatment of breast cancer, 877
combined with doxorubicin, cyclophosphamide, and lomustine versus cyclophosphamide, doxorubicin, and cisplatin in the treatment of advanced adenocarcinoma-large cell carcinoma of the lung: a North Central Cancer Treatment Group study, 493
combined with 5-FU, mitomycin, and vincristine in the treatment of metastatic colorectal carcinoma, 647
combined with 5-FU, vincristine, bleomycin, cyclophosphamide, and mitomycin in the treatment of metastatic urinary bladder cancer, 1167
combined with mitomycin and vincristine, phase II study of, in advanced adenocarcinoma of the lung, 1299
combined with prednisone, 5-FU, doxorubicin, and cyclophosphamide (PM-FAC), aggressive doxorubicin-containing regimen, in disseminated estrogen receptor-negative breast cancer, 1017
combined with vincristine and bleomycin (VBM), multidrug chemotherapy, and radiotherapy in stage III–IV squamous cell carcinoma of the head and neck, 1019
cyclophosphamide, and 5-FU (CMF), -induced nausea and vomiting: a controlled study with high-dose metoclopramide, 921
and cyclophosphamide, evaluation of, in the treatment of metastatic carcinoid tumor and the malignant carcinoid syndrome, 665
effect of vitamin C on the excretion of, 446
and 5-FU, sequenced, tamoxifen and conjugated estrogens (Premarin) followed by, in refractory advanced breast cancer, 1421
plus 5-FU, sequential, in advanced breast and colorectal cancers, phase II study of, 547
and 5-FU, sequential, in breast cancer resistant to the conventional application of these drugs, 1279
and 5-FU, sequential, in CMFP (cyclophosphamide, methotrexate, 5-FU, and prednisone) therapy for breast cancer, 877
high-dose with leucovorin rescue, combined with vinblastine and bleomycin, with or without tamoxifen, in metastatic renal cell carcinoma, 587
high-dose, with leucovorin rescue plus vincristine in advanced sarcoma: a Southwest Oncology Group study, 409
-leucovorin rescue plus cyclophosphamide (MECY)-cisplatin versus cisplatin-CHAD (cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin) as initial chemotherapy in stage III–IV ovarian adenocarcinoma, 1433
low-dose, treatment of advanced soft tissue sarcomas with: a phase II trial by the European Organization for Research on Treatment of Cancer Soft Tissue and Bone Sarcoma Group, 683
and mitoxantrone, use of a human tumor cloning system to evaluate analogs of, 733
pharmacokinetics of, in adult Indian patients and its relationship to nutritional status, 727
probenecid inhibition of, cytotoxicity in mouse L1210 leukemia cells, 521
sequential, and 5-FU plus mitomycin and leucovorin in patients with disseminated large bowel cancer, phase II study of: a Northern California Oncology Group study, 983
sequential continuous infusion with doxorubicin and vinblastine: an effective chemotherapy combination for patients with advanced breast cancer previously treated with, combined with cyclophosphamide, 5-FU, vincristine, and prednisone, 1039
with thymidine protection or rescue in advanced head and neck cancer, phase II study of, 543
Methylazoxymethanol, -treated rats, inhibition of intestinal tumorigenesis in, by dietary restriction, 405
***N*-Methylformamide**, phase I trial of, 607
Methylprednisolone, and chlorpromazine alone or in combination for the control of cisplatin-induced emesis, 1310
Metoclopramide
antiemetic therapy: a review of recent studies and a report of a random assignment trial compared to delta-9-tetrahydrocannabinol, 163
high-dose, controlled study: cyclophosphamide, methotrexate, and 5-FU (CMF)-induced nausea and vomiting, 921
Metoprine, phase II evaluation of, in advanced pancreatic adenocarcinoma, 1053
Metronidazole, oral, combined with iv mitomycin, phase I study of, 1191
Mithramycin, hepatic toxicity of low doses of, in hypercalcemia, 1379
Mitoguazone
phase II trial of, in patients with advanced head and neck cancer, 1301

phase II trial of, in patients with relapsed small cell carcinoma of the lung, 561
Mitolactol
activity of, in cancer of the uterine cervix, 669
and dacarbazine, phase II trial of vinblastine, bleomycin, and cisplatin (VBP) followed by, in metastatic melanoma, 1395
phase II study of, in chemotherapy-refractory metastatic breast cancer, 1499
phase II trial of, in previously treated and untreated patients with advanced colorectal cancer: an Illinois Cancer Council trial, 1303
Mitomycin
combined with 5-FU, vincristine, and methotrexate in the treatment of metastatic colorectal carcinoma, 647
combined with 5-FU, vincristine, bleomycin, cyclophosphamide, and methotrexate in the treatment of metastatic urinary bladder cancer, 1167
combined with methotrexate and vincristine in advanced adenocarcinoma of the lung, phase II study of, 1299
combined with vinblastine versus cyclophosphamide, doxorubicin, and etoposide (EST 2575, generation IV): chemotherapy for metastatic non-small cell bronchogenic carcinoma, 1325
and doxorubicin or cisplatin and etoposide, combination chemotherapy for non-small cell lung cancer, 1079
high-dose, phase I–II study of, with autologous bone marrow transplantation in refractory metastatic breast cancer, 805
iv, combined with oral metronidazole, phase I study of, 1191
regional intra-arterial, infusion in previously treated patients with metastatic colorectal cancer and concomitant measurement of serum drug level, 1319
sequential, and leucovorin plus methotrexate and 5-FU in patients with disseminated large bowel cancer, phase II study of: a Northern California Oncology Group study, 983
Mitoxantrone
and cyclophosphamide in patients with advanced breast cancer, 1283
and doxorubicin, myocardial effects of, in the mouse and guinea pig, 841
and methotrexate, use of human tumor cloning system to evaluate analogs of, 733
phase II clinical trial of, in advanced renal cell carcinoma: a Southwest Oncology Group study, 919
phase II evaluation of, in patients with bronchogenic carcinoma: a Southeastern Cancer Study Group trial, 1295
phase II study of, in advanced breast cancer: an Eastern Cooperative Oncology Group pilot study, 1511
phase II trial of, in patients with primary liver cancer, 1313
in the treatment of malignant melanoma, 903
treatment of metastatic sarcomas with, 813
Monoclonal antitumor antibodies, in the lymphatics, 257
MOPP (mechlorethamine, vincristine, prednisone, and procarbazine), -resistant advanced Hodgkin's disease, doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) salvage of, 947
Myeloma *see* Cancer, myeloma

N

Neuroblastoma *see* Cancer, neuroblastoma

O

Origins and development of chemotherapy research at the National Cancer Institute, 9
Ovarian cancer *see* Cancer, ovarian

P

PACCO (cisplatin, doxorubicin, cyclophosphamide, lomustine, and vincristine), in the treatment of non-small cell bronchogenic carcinoma, 771
PALA
combined with amsacrine, teniposide, and zinostatin in small cell lung carcinoma (EST 2579): phase II study of, 1183
combined with thymidine and 5-FU (biochemically designed combination), phase I evaluation of, 539
and 5-FU, continuous-infusion, phase I study of, 531
and PCNU, phase II study of, in the treatment of non-small cell lung cancer (EST 2580): an Eastern Cooperative Oncology Group study, 1297
phase II trial of, in lymphoma: an Eastern Cooperative Oncology Group study, 551
Pancreatic cancer *see* Cancer, pancreatic
PCNU
and PALA, phase II study of, in the treatment of non-small cell lung cancer (EST 2580): an Eastern Cooperative Oncology Group study, 1297
phase II study of, in the treatment of head and neck cancer, 437
phase II trial of, in advanced renal cell carcinoma and malignant melanoma, 1049
phase II trial of, in children with recurrent brain tumors and Hodgkin's disease, 441
treatment for recurrent malignant gliomas, 969
Pentamethylmelamine, versus hexamethylmelamine, phase II trial of, in the treatment of carcinoma of the bilharzial bladder, 793
Pharmacokinetics
arterial drug infusion with extracorporeal removal: theoretic basis with particular reference to the brain, 373
and clinical results: doxorubicin (75 mg/m^2) for hepatocellular carcinoma, 487
of free and total platinum species after short-term infusion of cisplatin, 505
of methotrexate in adult Indian patients and its relationship to nutritional status, 727
plasma, and tissue distribution of thiotepa in mice, 1265
studies of anticancer drugs in tumor-bearing animals, 381
Phase I studies
of anthracenedicarboxaldehyde in patients with refractory adult acute leukemia, 535
of carboplatin daily for 5 days, 1103
of cytarabine and cisplatin in patients with advanced cancer, 1097
of diaziquone, 975
of high-dose etoposide for refractory malignancies, 1471
of homoharringtonine, 1085
of immunotherapy by live *Brucella abortus* (strain 19 BA) in cancer patients, 417

of intermittent high-dose dacarbazine, 499
of *N*-methylformamide, 607
of PALA, thymidine, and 5-FU (biochemically designed combination), 539
of teroxirone, 1115
of vinzolidine, 979
of weekly high-dose human lymphoblastoid interferon, 1093
Phase II studies
of acivicin in colorectal carcinoma: a National Cancer Institute of Canada study, 1121
of amsacrine in children with advanced metastatic neuroblastoma, 1051
of amsacrine in colorectal, gastric, and pancreatic carcinomas: a Southeastern Cancer Study Group trial, 929
of amsacrine in metastatic or locally recurrent squamous cell carcinoma from head and neck primaries: a Southwest Oncology Group study, 435
of amsacrine in pancreatic carcinoma: a Southwest Oncology Group study, 1411
of amsacrine in patients with hepatoma: a Cancer and Leukemia Group B study, 923
of amsacrine in the treatment of metastatic ovarian carcinoma: a Cancer and Leukemia Group B study, 1397
of anthracenedicarboxaldehyde in patients with refractory adult acute leukemia, 535
of bisantrene in advanced epidermoid carcinoma of the head and neck, 687
of bisantrene in advanced refractory small cell lung cancer, 927
of bleomycin in patients with advanced epithelial ovarian cancer, 549
of chlorozotocin in patients with myeloma, 685
of chlorozotocin in refractory multiple myeloma, 1409
of cisplatin in advanced gastric cancer, 1497
of 13-*cis*-retinoic acid in patients with advanced nonseminomatous germ cell tumors, 1287
of continuous 5-day vinblastine in renal adenocarcinoma, 925
of continuous-infusion vinblastine in the treatment of refractory epithelial carcinoma of the ovary, 1417
of 4-demethoxydaunorubicin in advanced colorectal carcinoma, 689
of 4-demethoxydaunorubicin in patients with adenocarcinoma of the upper gastrointestinal tract, 1415
of 4-demethoxydaunorubicin in patients with non-small cell lung cancer, 563
of diaziquone in advanced renal adenocarcinoma, 1055
of diaziquone in patients with advanced carcinoma of the lung, 1193
of doxorubicin and bleomycin in hepatocellular carcinoma: a Southeastern Cancer Study Group trial, 1517
of 4′-epi-doxorubicin in advanced breast cancer, 1285
of 4′-epi-doxorubicin in metastatic melanoma, 1509
of 4′-epi-doxorubicin in patients with advanced malignant melanoma, 679
of 4′-epi-doxorubicin in patients with metastatic colorectal carcinoma, 1507
of etoposide in advanced prostate cancer, 1195
of etoposide in previously treated small cell carcinoma of the lung, 1413
of etoposide in the management of advanced or recurrent nonsquamous cell carcinoma of the cervix: a Gynecologic Oncology Group study, 1513
of 5-FU administered ip to patients with refractory ovarian cancer, 1229
of 5-FU, cyclophosphamide, ifosfamide, and vincristine in carcinoma of the bilharzial bladder, 419
of hexamethylmelamine versus pentamethylmelamine in carcinoma of the bilharzial bladder, 793
of human leukocyte (alpha) interferon in metastatic malignant melanoma: the American Cancer Society trial, 723
of ICRF-187 in squamous cell carcinoma of the head and neck, 427
of intermittent iv homoharringtonine in the treatment of refractory epithelial carcinoma of the ovary, 1503
of iv mitomycin and oral metronidazole, 1191
of low-dose methotrexate in advanced soft tissue sarcomas: a European Organization for Research on Treatment of Cancer Soft Tissue and Bone Sarcoma Group study, 683
of methotrexate with thymidine protection or rescue in advanced head and neck cancer, 543
of metoprine in advanced pancreatic adenocarcinoma, 1053
of mitoguazone in patients with advanced head and neck cancer, 1301
of mitoguazone in patients with relapsed small cell carcinoma of the lung, 561
of mitolactol for malignant melanoma, 1045
of mitolactol in chemotherapy-refractory metastatic breast cancer, 1499
of mitolactol in previously treated and untreated patients with advanced colorectal cancer: an Illinois Cancer Council trial, 1303
of mitomycin, methotrexate, and vincristine combination chemotherapy in advanced adenocarcinoma of the lung, 1299
of mitoxantrone in advanced breast cancer: an Eastern Cooperative Oncology Group pilot study, 1511
of mitoxantrone in advanced renal cell carcinoma: a Southwest Oncology Group study, 919
of mitoxantrone in patients with bronchogenic carcinoma: a Southeastern Cancer Study Group trial, 1295
of mitoxantrone in patients with primary liver cancer, 1311
multicenter, of 5-day continuous-infusion vinblastine in metastatic malignant melanoma, 1199
of PALA, amsacrine, teniposide, and zinostatin in small cell lung carcinoma: EST 2579, 1183
of PALA and PCNU in the treatment of non-small cell lung cancer (EST 2580): an Eastern Cooperative Oncology Group study, 1297
of PALA in lymphoma: an Eastern Cooperative Oncology Group study, 551
of PCNU in advanced renal cell carcinoma and malignant melanoma, 1049
of PCNU in children with recurrent brain tumors and Hodgkin's disease, 441
of PCNU in the treatment of head and neck cancer, 437
of prednimustine in glioblastoma multiforme, 795
of prospidin in recurrent head and neck carcinoma, 915
of razoxane in the management of recurrent adenocarcinoma of the ovary: a Gynecologic Oncology Group study, 439
of sequential methotrexate and 5-FU plus mitomycin and leucovorin in patients with disseminated large bowel cancer: a Northern California Oncology Group study, 983
of sequential methotrexate plus 5-FU in advanced breast and colorectal cancers, 547

of spirogermanium in advanced breast cancer, 1515
of spirogermanium in advanced renal cell carcinoma: a Cancer and Leukemia Group B study, 1305
of spirogermanium in the treatment of metastatic breast cancer, 1197
of tamoxifen in advanced endometrial adenocarcinoma: a Gynecologic Oncology Group study, 809
of teniposide in refractory ovarian cancer, 815
of teniposide in small cell carcinoma of the lung, 1289
of vinblastine, bleomycin, and cisplatin (VBP) followed by dacarbazine and mitolactol in metastatic melanoma, 1395
of vindesine, cisplatin, and hexamethylmelamine (VCH) in small cell carcinoma of the lung, 1179
of vindesine in adenocarcinoma of the lung, 557
of vindesine in advanced squamous cell cancer of the head and neck, 559
of vindesine in the treatment of advanced colorectal cancer, 555
of vindesine in the treatment of malignant glioma, 807
of vinzolidine, an oral vinca alkaloid, in Hodgkin's disease and non-Hodgkin's lymphoma, 1399
of weekly low-dose 4'-epi-doxorubicin in advanced postmenopausal breast cancer, 675

Phase I–II studies
of aclarubicin for treatment of acute myeloid leukemia, 881
of the continuous infusion of doxorubicin in the treatment of non-small cell lung cancer, 681
of diaziquone chemotherapy in brain tumors, 913
of high-dose mitomycin with autologous bone marrow transplantation in refractory metastatic breast cancer, 805

Phosphoramide mustard, and 4-hydroxycyclophosphamide, plasma concentrations of, in patients repeatedly given high doses of cyclophosphamide in preparation for bone marrow transplantation, 1247

Pipobroman, efficacy trial of, in essential thrombocythemia: a study of 24 patients, 1339

PM-FAC (prednisone, methotrexate, 5-FU, doxorubicin, and cyclophosphamide), aggressive doxorubicin-containing regimen, in disseminated estrogen receptor-negative breast cancer, 1017

POC (procarbazine, vincristine, and lomustine), combination cytotoxic chemotherapy with, in disseminated malignant melanoma: 8 years' follow-up, 1211

Potential use of analogs of luteinizing hormone-releasing hormones in the treatment of hormone-sensitive neoplasms, 281

Preclinical New Drug Research Program of the National Cancer Institute, 63

Predictive tests, for the response to cancer chemotherapy: limitations related to the prediction of rare events, 611

Prednimustine, phase II trial of, in glioblastoma multiforme, 795

Prednisolone, effect of, on hormone profiles during primary endocrine treatment of advanced breast cancer, 1447

Prednisone
combined with cyclophosphamide, methotrexate, and 5-FU (CMFP), sequential methotrexate and 5-FU in, in the treatment of breast cancer, 877
combined with methotrexate, 5-FU, doxorubicin, and cyclophosphamide (PM-FAC), aggressive doxorubicin-containing regimen, in disseminated estrogen receptor-negative breast cancer, 1017
combined with vincristine, carmustine, and doxorubicin (VBAP), addition of cisplatin and bleomycin to, in the treatment of relapsing or resistant multiple myeloma: a Southwest Oncology Group study, 481
combined with vindesine, carmustine, and doxorubicin (EBAP) in recurrent lymphomas: a Southwest Oncology Group study, 963
mechlorethamine, vincristine, and procarbazine (MOPP)-resistant advanced Hodgkin's disease, doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) salvage of, 947
and melphalan, intermittent high-dose, and human leukocyte interferon administration in the treatment of multiple myeloma: a randomized clinical trial from the Myeloma Group of Central Sweden, 1331
sequential continuous infusion with doxorubicin and vinblastine: an effective chemotherapy combination for patients with advanced breast cancer previously treated with, combined with cyclophosphamide, methotrexate, 5-FU, and vincristine, 1039
and vincristine, alternating pulses of vincristine and prednisone with cytarabine and cyclophosphamide versus, in the maintenance therapy of acute lymphoblastic leukemia, 581

Probenecid, enhancement of cisplatin nephrotoxicity by, 445

Procarbazine
combined with vincristine and lomustine (POC) in the treatment of disseminated malignant melanoma: 8 years' follow-up, 1211
mechlorethamine, vincristine, and prednisone (MOPP)-resistant advanced Hodgkin's disease, doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) salvage of, 947

Promise of radiosensitizers and radioprotectors in the treatment of human cancer, 291

Prospidin, phase II study of, in recurrent head and neck carcinoma, 915

Prostatic cancer *see* Cancer, prostatic

PVB (cisplatin, vinblastine, and bleomycin), treatment of malignant germ cell tumors of the ovary with, 779

R

Radiation therapy
and chemotherapy, acute myelogenous leukemia following, for osteogenic sarcoma, 909
combined iridium 192 interstitial and external beam radiation therapy for the treatment of prostatic cancer, 1027
double hemibody, in chemotherapy-resistant multiple myeloma, 1173
-induced taste aversion as a factor in cancer therapy, 1219
multidrug chemotherapy (vincristine, bleomycin, and methotrexate; VBM) with, in stage III–IV squamous cell carcinoma of the head and neck, 1019
particle-beam, 1983: evaluation and recommendations, 303
role of, in local tumor control: management of Ewing's sarcoma, 703
versus surgery: local treatment of Ewing's sarcoma, 695

Radioimmunoassay, sensitive, for cytarabine and uracil arabinoside in plasma, 1357

Razoxane
and doxorubicin treatment, concomitant, on a weekly schedule, 1035
phase II trial of, in the management of recurrent adenocarci-

noma of the ovary: a Gynecologic Oncology Group study, 439
Regional cancer chemotherapy, 101
Renal cancer *see* Cancer, renal
Renal cell cancer *see* Cancer, renal cell
Report of the Cancer Chemotherapy Collaborative Program Review Committee: the Richardson Report, 343
13-*cis*-Retinoic acid, phase II trial of, in patients with advanced nonseminomatous germ cell tumors, 1287
Retinol, oral, plasma kinetics of, in cancer patients, 1125
Review of the Report of the 1966 Cancer Chemotherapy Collaborative Program Review Committee, 340
Rhabdomyosarcoma *see* Tumor systems, animals
RIF tumors *see* Tumor systems, animals

S

Sarcoma *see* Cancer, sarcoma
Serial interferon alpha$_2$ levels, in serum and cerebrospinal fluid, 1057
Sodium thiosulfate, high-dose iv (cisplatin's antidote), and ip cisplatin, "two-route chemotherapy" using, for peritoneally disseminated cancer in mice, 1367
On Special Initiatives, Critics, and the National Cancer Program, 1
Spirogermanium
phase II study of, in advanced breast cancer, 1515
phase II study of, in the treatment of metastatic breast cancer, 1197
phase II trial of, in advanced renal cell carcinoma: a Cancer and Leukemia Group B study, 1035
pulmonary toxicity associated with, 907
Surgical treatment
surgical oncology research development: the perspective of the National Cancer Institute, 825
surgical resection and limited chemotherapy for abdominal undifferentiated lymphomas, 599
versus radiation therapy: local treatment of Ewing's sarcoma, 695

T

Tamoxifen
and aminoglutethimide, thrombocytopenia after combination therapy with: which drug is to blame?, 1015
combined with cisplatin, carmustine, and dacarbazine in metastatic melanoma, 1403
and conjugated estrogens (Premarin) followed by sequenced methotrexate and 5-FU in refractory advanced breast cancer, 1421
high-dose methotrexate with leucovorin rescue, vinblastine, and bleomycin, with or without, in metastatic renal cell carcinoma, 587
phase II clinical study of, in advanced endometrial adenocarcinoma: a Gynecologic Oncology Group study, 809
venous thrombosis as a side effect of, 887
Teniposide
combined with PALA, amsacrine, and zinostatin in small cell lung carcinoma (EST 2579), phase II study of, 1183
phase II study of, in small cell carcinoma of the lung, 1289
a review of 12 years of experience, 1455
in the treatment of refractory ovarian cancer, phase II study of, 815
Teroxirone, phase I trial of, 1115
Testicular cancer *see* Cancer, testicular
Thiotepa, plasma pharmacokinetics and tissue distribution of, in mice, 1265
Thymidine
combined with PALA and 5-FU (biochemically designed combination), phase I evaluation of, 539
protection or rescue, methotrexate with, in advanced head and neck cancer, phase II study of, 543
Thymoma *see* Cancer, thymoma
Tomography, computerized cranial, role of, in the staging of small cell carcinoma of the lung, 1375
Treatment of chemotherapy extravasation: current status, 939
Trophoblastic disease, gestational, oral etoposide in, 775
Tumor stem cell heterogeneity: implications with respect to classification of cancers by chemotherapeutic effect, 43
Tumor systems, animals
L1210 leukemia
-bearing mice, effects of 5-aza-2′-deoxycytidine in combination with the biochemical modulator thymidine or the immune modulator pyran copolymer on, 1255
chemotherapy-increased antineoplastic effects of antibody-toxic conjugates, 643
effects of dose and duration of exposure on 5-aza-2′-deoxycytidine cytotoxicity for, in vitro, 1475
intracerebral, antileukemic activity of 5-aza-2′-deoxycytidine and cytarabine against, 1483
rhabdomyosarcoma, rat, amplified pulmonary metastases of, in response to nitrosourea treatment, 749
RIF tumors, responses of, to heat and drugs: dependence on tumor size, 1149
Thymoma *see* Cancer, thymoma

U

Uracil arabinoside
acute cerebellar toxicity after high-dose cytarabine associated with CNS accumulation of its metabolite, 1309
and cytarabine, sensitive radioimmunoassay for, in plasma, 1357

V

VBAP (vincristine, carmustine, doxorubicin, and prednisone), addition of cisplatin and bleomycin to, in the treatment of relapsing or resistant multiple myeloma: a Southwest Oncology Group study, 481
VBM (vincristine, bleomycin, and methotrexate), multidrug chemotherapy, with radiotherapy in stage III–IV squamous cell carcinoma of the head and neck, 1019
VBP (vinblastine, bleomycin, and cisplatin), followed by dacarbazine and mitolactol in metastatic melanoma, 1395
VCH (vindesine, cisplatin, and hexamethylmelamine), in small cell carcinoma of the lung: phase II study of, 1179
Vinblastine
active chemotherapy regimen for squamous cell lung cancer, 475
combined with bleomycin and cisplatin (VBP) followed by da-

carbazine and mitolactol in metastatic melanoma, phase II trial of, 1395
combined with cisplatin and bleomycin (CVB) for relapsed disseminated neuroblastoma, 1157
combined with cisplatin and bleomycin (PVB) in the treatment of malignant germ cell tumors of the ovary, 779
combined with cisplatin and bleomycin, response of a hepatocellular carcinoma to, 1419
combined with high-dose methotrexate with leucovorin rescue and bleomycin, with or without tamoxifen, in metastatic renal cell carcinoma, 587
combined with mitomycin versus cyclophosphamide, doxorubicin, and etoposide (EST 2575, generation IV): chemotherapy for metastatic non-small cell bronchogenic carcinoma, 1325
continuous 5-day infusion, phase II study of, in renal adenocarcinoma, 925
continuous-infusion, for treatment of refractory epithelial carcinoma of the ovary, phase II trial of, 1417
doxorubicin, bleomycin, and dacarbazine (ABVD) salvage of mechlorethamine, vincristine, prednisone, and procarbazine (MOPP)-resistant advanced Hodgkin's disease, 947
and doxorubicin, sequential continuous infusion with: an effective chemotherapy combination for patients with advanced breast cancer previously treated with cyclophosphamide, methotrexate, 5-FU, vincristine, and prednisone, 1039
evaluation of, administered by 5-day continuous infusion in women with advanced breast cancer, 803
increase of serum iron concentrations in rhesus monkeys and humans on administration of, 933
of vindesine administration, dyspnea following, in patients receiving mitomycin plus vinca alkaloid combination therapy, 1029

Vincristine
acquisition of multiple drug resistance by CCRF-CEM cells selected for different degrees of resistance to, 831
combined with bleomycin and methotrexate (VBM), multidrug chemotherapy, and radiotherapy in stage III–IV squamous cell carcinoma of the head and neck, 1019
combined with carmustine, doxorubicin, and prednisone (VBAP), addition of cisplatin and bleomycin to, in the treatment of relapsing or resistant multiple myeloma: a Southwest Oncology Group study, 481
combined with cisplatin, cyclophosphamide, and doxorubicin in the treatment of non-small cell lung cancer, 1159
combined with 5-FU, bleomycin, cyclophosphamide, mitomycin, and methotrexate in the treatment of metastatic urinary bladder cancer, 1167
combined with 5-FU, mitomycin, and methotrexate in the treatment of metastatic colorectal carcinoma, 647
combined with methotrexate, bleomycin, doxorubicin, cyclophosphamide, and dexamethasone in the treatment of advanced non-Hodgkin's lymphomas other than diffuse histiocytic or undifferentiated histologies, 1343
combined with mitomycin and methotrexate, phase II study of, in advanced adenocarcinoma of the lung, 1299
combined with procarbazine and lomustine (POC) in the treatment of disseminated malignant melanoma: 8 years' follow-up, 1211
plus high-dose methotrexate with leucovorin rescue in advanced sarcoma: a Southwest Oncology Group study, 409
increase of serum iron concentrations in rhesus monkeys and humans on administration of, 933
mechlorethamine, prednisone, and procarbazine (MOPP)-resistant advanced Hodgkin's disease, doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) salvage of, 947
phase II chemotherapy trial of, in cancer of the bilharzial bladder, 419
and prednisone, alternating pulses of vincristine and prednisone with cytarabine and cyclophosphamide versus, in the maintenance therapy of acute lymphoblastic leukemia, 581
sequential continuous infusion with doxorubicin and vinblastine: an effective chemotherapy combination for patients with advanced breast cancer previously treated with, combined with cyclophosphamide, methotrexate, 5-FU, and prednisone, 1039

Vindesine
carmustine, doxorubicin, and prednisone (EBAP) in recurrent lymphomas: a Southwest Oncology Group study, 963
and cisplatin, treatment of recurrent small cell lung carcinoma with, 791
combined with cisplatin and hexamethylmelamine (VCH) in the treatment of small cell carcinoma of the lung: phase II study of, 1179
combined with etoposide and cisplatin in patients with previously treated, advanced-stage, non-small cell lung cancer, 413
5-day continuous-infusion, multicenter phase II trial with, in metastatic malignant melanoma, 1199
evaluation of, in patients with refractory small cell lung cancer, 1407
increase of serum iron concentrations in rhesus monkeys and humans on administration of, 933
phase II evaluation of, in the treatment of malignant glioma, 807
phase II study of, in the treatment of advanced colorectal carcinoma, 555
phase II trial of, in adenocarcinoma of the lung, 557
phase II trial of, in advanced squamous cell cancer of the head and neck, 559
treatment of esophageal cancer with: an open trial, 783
or vinblastine administration, dyspnea following, in patients receiving mitomycin plus vinca alkaloid combination therapy, 1029
warfarin, and etoposide interactions, 817

Vinzolidine
phase I trial of, 979
phase II trial of, an oral vinca alkaloid, in Hodgkin's disease and non-Hodgkin's lymphoma, 1399

Vitamin C, effect of, on the excretion of methotrexate, 446

W

Warfarin, etoposide, and vindesine interactions, 817

X

D-Xylose absorption, use of decline in, to predict infection following intensive chemotherapy, 1489

Z

Zinostatin, combined with PALA, amsacrine, and teniposide in small cell lung carcinoma (EST 2579): phase II study of, 1183

Author Index

A

Aalders JG, 779
Aapro MS, 1493
Abecasis MN, 471
Abbruzzese JL, 1375
Adams JW, 565
Adinolfi D, 1505
Adler SS, 423
Agarwal RP, 1309
Ahmann DL, 803
Ahmed T, 689
Ahre A, 1331
Aisner J, 859, 939, 1103
Ajani JA, 1085, 1507
Akman SR, 1265
Akolkar PN, 727
Alavi JB, 807
Albain KS, 413
Alberto P, 563, 1079
Alberts DS, 367, 765, 1125, 1493
Aldenderfer P, 859
Alexanian R, 481
Allegra JC, 1395
Allen J, 441
Alonso MT, 1455
Amato KR, 411
Ambrosetti A, 947
Ames MM, 975
Amrein PC, 923, 1397
Andersen J, 795
Anderson KC, 1343
Antman K, 1413
Antoine E, 749
Aoki K, 1367
Appelqvist P, 915
Ardalan B, 531
Arena F, 689
Armentrout S, 1419
Aroney RS, 587, 859
Atad J, 891
Avellanosa A, 913

B

Baba T, 1367
Baehner RL, 1269
Baguley BC, 625
Baker DL, 1219
Baker LH, 409, 919, 1047, 1411
Baker SR, 427
Balcerzak SP, 409, 919, 1411
Barbati S, 1310
Bareford D, 1033
Barlow JJ, 1433
Barnard D, 1033
Barrelet L, 1079
Bartolucci AA, 813, 903, 929, 1409, 1517
Bartsch H, 1279
Bateman JR, 1035
Battista C, 1310
Baum E, 661
Baum JG, 329
Beaudry J, 1125
Beaumier P, 317
Beck TM, 647
Beck WT, 831
Bell DR, 587
Beltran J, 1199
Bender KS, 1043
Bennett JM, 1351, 1497, 1511
Benz C, 429
Berd D, 207
Berman E, 679
Bernasconi C, 1339
Bernstein ID, 1269
Bertrand M, 651
Bezwoda WR, 783
Bhardwaj S, 1397
Bhimani S, 913
Bilek FS, 1219
Birch B, 423
Birch R, 1295
Bitran JD, 413, 817
Bjorkholm M, 1331
Blackburn AM, 1447
Blackledge G, 549
Blanc A-P, 471
Blessing JA, 439, 809, 1513
Bleyer WA, 521, 661
Bloch A, 199
Bloch B, 891
Block JB, 487, 631
Block M, 719
Blomqvist C, 655
Blough RR, 413
Blum RH, 681, 1383
Blumenreich MS, 1395
Blumenschein GR, 805, 1039, 1197
Blumsack JT, 1219
Bodey GP, 437, 907, 1085, 1197, 1507
Bofenkamp TM, 565
Bonnet JD, 481
Bonomi P, 1163
Bontoux D, 1173

Boon MH, 1239
Booser DJ, 671
Borasi F, 1019
Bordin LA, 163
Borison HL, 401
Bork E, 1289
Bosl GJ, 1287, 1301
Bostrom B, 1157
Bottino JC, 681
Bouma J, 779
Boutselis JG, 443
Bowden GT, 367
Bowers MW, 1049
Bowman DM, 1421
Brain JD, 759
Braine HG, 711
Bramwell V, 683
Brandt EN, Jr, 5
Brenning G, 1331
Bricker LJ, 427
Brincker H, 1233
Broder LE, 659
Broggini M, 739
Bromer RH, 1375
Browman GP, 465
Brown JP, 317
Bruera E, 873
Bruno LA, 807
Brusamolino E, 1339
Bruyland M, 787
Bryan GT, 925
Brzechwa-Adjukiewicz A, 487
Buchanan R, 1295
Buckley H, 549
Budman DR, 979
Buesa JM, 499, 683
Bui BN, 921
Bulbrook RD, 1447
Bull F, 1035
Bunn PA, Jr, 1439
Buoncristiani P, 1505
Burk MW, 723
Burke MT, 1029
Burke PJ, 1043
Buskard N, 1015
Bustelo P, 581
Butler TP, 1049
Butti G, 1505
Buzdar AU, 1039
Byrne MJ, 1045
Byrne RE, 1375

C

Cadman EC, 429, 877, 1159
Calculli G, 1051
Calman KC, 547
Camacho FJ, 559, 1497
Campora E, 1019, 1285
Canegrati MA, 643
Canellos GP, 1343, 1413
Canevari A, 1339
Carbone PP, 771
Carcassonne Y, 471
Carli M, 1051
Carmo-Pereira J, 1211
Carney DN, 1439
Carr DT, 671
Carrano RA, 841
Carraro S, 873
Carrasquillo JA, 317
Cartei G, 1205
Case DC, Jr, 1343
Casper ES, 539, 679
Catalano RB, 1499
Catane R, 1191
Cavalli F, 563, 1079
Ceci A, 1051
Cedaro L, 873
Cellerino R, 947
Cetto G, 947
Chabner BA, 87
Chabot GG, 1483
Chacón R, 873
Chahinian AP, 566
Champlin RE, 145
Chan KK, 487
Chang AYC, 1407, 1515
Chang F-F, 651
Chapman R, 561
Chard RL, 1269
Chauvergne J, 921
Chen TT, 1023, 1411
Cheng EW, 689, 1053, 1415
Chiuten DF, 671
Chlebowski RT, 487, 631, 1035
Choo YC, 775
Christensen L, 795
Citron ML, 475
Civin CI, 1043
Clark GM, 557, 927
Clark RA, 163
Clendeninn NJ, 87
Clubb BS, 1027
Coates AS, 1045
Coetzer BJ, 1311
Cohen HJ, 1409
Cohen MH, 475, 1439
Coleman M, 923, 1397
Collins JM, 373
Colombo N, 815
Colombo T, 739
Coltman CA, Jr, 927, 1411
Comaru-Schally AM, 281
Congdon JE, 983
Connors JM, 1093
Conroy JF, 439
Conter V, 831
Copeland LJ, 1503
Copley MP, 999
Coren A, 551
Cornell CJ, Jr, 685
Costa RR, 1199

Costanzi JJ, 1025, 1047, 1411
Coughlin CT, 591
Covell DG, 257
Covey JM, 1255, 1475
Cowan JD, 357
Cowden A, 487
Crain SM, 687
Crawford ED, 1025
Creagan ET, 975, 1193
Creasman WT, 809
Creech RH, 1183, 1297, 1325, 1499
Cripps C, 1121
Cross J, 877
Crossling F, 547
Crowther D, 549
Cullinan S, 493
Cummings KB, 719
Curt GA, 87, 825
Curtis PW, 647

D

Daban A, 1173
Daley-Yates PT, 445
Daly KM, 1489
Daniele O, 1205
Daugaard G, 1179
David C, 417
David M, 921
Davis RB, 1305
Day R, 1325
Dazord L, 417
DeBernardi B, 1051
de Cesare M, 1310
Decker DA, 1047
Dedrick RL, 373
Degnan TJ, 979
de Gramont A, 1467
Delage J-M, 1467
Delgado M, 881
DeLos Santos R, 913
Del Prete SA, 1403
DeMeester TR, 413
Derman DP, 783
Dermody WC, 859
Derocher D, 1115
de Vassal F, 881
DeVita VT, Jr, 1, 339
de Vries EGE, 1471
Dhingra HM, 671
Diaz-Rubio E, 555
Dibar E, 581
Dicke K, 805
Dierks KM, 1499
Dietrich MF, 631
Dimery IW, 437
di Montezemolo LC, 1051
Dinapoli RP, 431
D'Incalci M, 381, 815
DiStefano A, 805
Dixon C, 671, 907
Dixon DO, 435, 481, 963
Doeden D, 1247
Dombernowsky P, 1289
Donehower M, 535
Donehower RC, 1379
Donelli MG, 381, 739
Drasga RE, 818
Driscoll JS, 63
Drivsholm A, 1233
Drolet Y, 1467
Dubbelman R, 607
Dubin N, 1383
Durand M, 921

E

Eagan RT, 431, 493, 975, 1193
Earhart R, 1297
Earle MF, 447
Eastman A, 1189
Ebinger G, 787
Eddy JL, 1439
Edmonson JH, 1063
Edmundson JM, 897
Edwards BK, 599
Egorin MJ, 1103, 1265
Ehninger G, 1283
Ehrsson H, 867
Einhorn LH, 567, 818, 1295
Einzig A, 1415
Eisenhauer E, 1121, 1421
Ellegaard J, 1233
Elliott T, 493
Elomaa I, 655
Elserafi M, 419, 793
Elslager E, 733
Engstedt L, 1331
Engstrom PF, 1273, 1497
Ensminger WD, 101
Eppinger-Helft M, 581
Epstein J, 1153
Erichson R, 1159
Ernst P, 1422
Estrada E, 499
Ettinger DS, 1183, 1297
Etzell P, 493
Evans RG, 703
Ewer M, 1085

F

Fabian CJ, 963
Falkson G, 1311, 1511, 1515
Farabegoli G, 1391
Farha P, 671
Farmer PS, 446
Faye L, 689
Ferguson C, 547
Ferguson LR, 625
Ferraro JA, 1183

Feun LG, 1307
Fidler IJ, 193
Fields AL, 1121
Fiorentino MV, 1205
Fisher B, 31
Fisher RJ, 587
Fleming TR, 493
Flesch M, 471
Flournoy N, 1017
Foley KM, 173
Forastiere AA, 687
Forcier RJ, 1403
Forman WB, 1409
Fornasiero A, 1205
Fosser VP, 1205
Fossieck BE, Jr, 475
Fox RM, 1045
Frank J, 1025
Fraser A, 446
Frei E, III, 21
Frelick RW, 1397
Freund L, 1233
Friedman MA, 983
Fritze D, 1279
Fruet F, 1391
Fryer C, 661
Frytak S, 975, 1193, 1427
Fuks Z, 1191
Fukushima S, 1167

G

Gad-el-Mawla N, 419, 793
Gaetani P, 1505
Gagliano RG, 1025
Gahrton G, 515, 1331
Gale ME, 1375
Gale RP, 145, 909
Gall HE, 505
Gallmeier WM, 1055
Galmuzzi G, 1310
Gams R, 813, 903, 1295
Gandara DR, 1509
Gandhour C, 417
Gangji D, 521
Garattini S, 381
Garaventa A, 1051
Garay G, 581
Garbino C, 687
Gastaut J-A, 471
Gastiaburu J, 881
Gaukroger JM, 1185
Geggie PHS, 1421
Geller NL, 1301
Gentile PS, 1395
George WD, 547
Gerad H, 535
Gerber L, 695
Gerrard J, 423
Gershenson DM, 1503
Gerstner JG, 803
Geurkink NA, 591
Giuntoli J, 581
Glass A, 1035
Glatstein E, 695
Glatte P, 799
Glaubiger DL, 521, 637
Glick JH, 551, 877, 1511
Godleski JJ, 759
Goepfert H, 437
Gokhale SV, 727
Gold EJ, 1287
Gold J, 1185
Goldberg G, 891
Goldberg J, 1351
Goldhirsch A, 1079
Goldschmidt E, 881
Goldstein LS, 855
Golomb HM, 413, 1351
Goodman GE, 1125
Goplerud DR, 1387
Gothoskar BP, 727
Grace M, 591
Gracia M, 499
Graham V, 1493
Gralla RJ, 163, 561, 1029
Grann V, 1159
Green L, 1379
Green M, 1305
Green MD, 681
Green SJ, 803
Grever MR, 1115
Gribble M, 983, 1509
Griffin T, 661
Grohn P, 915
Groover RV, 431
Groppe CW, Jr, 1017
Groshen S, 163
Grozea PN, 963, 1025
Gullo JJ, 1049
Gupta M, 1017
Gutierrez PL, 1265
Gyllenhammar H, 1331
Gyves JW, 101

H

Habeshaw T, 547
Hafström L, 867
Hagemeister F, 907
Hahn GM, 309, 1149
Hajba A, 915
Hamilton RW, 887
Hammond D, 661, 1269
Hamza R, 419, 793
Hancock C, 441
Hannigan EV, 443
Hannigan J, 983
Hansen HH, 1055, 1179, 1289
Hansen M, 1055
Hansen SW, 1422
Hardesty IJ, 1017

Harper GR, 1515
Harper HD, 689
Hart AAM, 505
Hart NE, 647
Harvey HA, 887
Harvey JH, 1049
Harwood KV, 939
Hasin Y, 1169
Haurani FI, 1397
Haut A, 481
Hedley DW, 1045
Heidemann EG, 1283
Heinonen E, 915
Hellstrom I, 317
Hellstrom KE, 317
Henderson E, 1305
Henriques E, 1211
Herbert BH, 849
Hermann RC, Jr, 431
Herrmann R, 1279
Herschkopf R, 1397
Herve P, 471
Hidalgo OF, 499
Higby D, 1351
Higgins G, 1269
Hilgers RD, 443
Hill GJ, 929
Hoare SA, 1447
Hochester H, 931
Hoerni B, 921
Hoffman PC, 413
Hogan TF, 719, 925
Holdener EE, 1055, 1079
Holland JF, 923
Hollander GR, 1219
Holm G, 1331
Holmström T, 655
Holopainen E, 915
Holton OD, III, 257
Homesley HD, 439, 809, 1513
Hong WK, 1375
Hortobagyi GN, 1039
Horton J, 877, 1511
Hoth DF, 1215
Howard J, 679
Howell SB, 361
Hubbard SM, 329, 825
Hug V, 1039
Hugander A, 867
Hulhoven R, 881
Hutcheon A, 547

I

Ignoffo RJ, 983
Ihde DC, 1439
Illenye S, 1189
Imondi AR, 841
Inamasu M, 1411
Ingle JN, 803
Isacoff WH, 631
Issell BF, 671
Italia C, 739
Itri LM, 1287
Iwamoto Y, 1367
Iwata N, 527

J

Jacobs AD, 909
Jacobs SA, 447
Jaffe N, 818
Jamin D, 531
Janus C, 599
Järnmark M, 1331
Jarrell R, 423
Jasmin C, 749
Jayaram HN, 531
Jenkins J, 1229
Jensen KB, 1233
Jensen MK, 1233
Johansson B, 1331
Johnson C, 1303
Johnston-Early A, 475
Jones SE, 963, 1399
Jones WG, 675
Jönsson P-E, 867
Joss RA, 563, 1079
Jungi F, 1279

K

Kaizer H, 711
Kalman LB, 163
Kampel LJ, 1277
Kan JS, 1043
Kanojia MD, 1507
Kao AK, 1383
Kao-Shan CS, 989
Kaplan BH, 559, 1389
Karasawa M, 527
Karnstrom L, 1331
Karp G, 1413
Kasdorf H, 687
Kasid A, 265
Kavanagh JJ, 1417, 1503
Kawai Y, 527
Kawano T, 1367
Kaye SB, 547
Keating M, 1085
Keenan AM, 257
Kelsen DP, 163, 561, 1415
Kemeny NE, 539, 689, 1053
Kendregan B, 651
Kennedy BJ, 1397
Kerr D, 723
Kessinger A, 439
Kessler J, 1493
Khaled H, 419, 793
Khandekar J, 1303, 1511, 1515
Kiang DT, 577

Killander A, 1331
King ME, 361
Kinsella TJ, 695
Kirkwood JM, 723
Kirshner J, 913, 1351
Klein I, 505
Klein L, 651
Kligerman MM, 303
Klimo P, 1299
Knerich R, 1505
Kobrin J, 565
Kodama K, 1357
Kohler M, 1509
Kongsholm H, 795
Krakoff IH, 1503
Kramer BS, 1295
Krasnow SH, 475
Kraut EH, 1115
Krebs H-B, 1387
Kreis W, 979
Kriel A, 891
Kris MG, 163, 1029
Krivit W, 1157, 1247
Krohn KA, 317
Krook JE, 493
Krown SE, 723
Kubota TT, 1395
Kubota Y, 1167
Kuebler JP, 925, 1515
Kuninaka A, 1357
Kurman MR, 1277
Kvicala R, 581
Kvols LK, 803
Kwa HG, 1447

L

Lacave AJ, 499
Lad TE, 568, 1303
Laine H, 655
Lampkin B, 661
Landoni F, 815
Lanzotti V, 1303
Larson RA, 1489
Larson SM, 317
Larzul JJ, 417
Lascaux V, 749
Lathan B, 733
Lawton F, 549
Layton DD, Jr, 431
Leclerc J-M, 1143
Lee ER, 309
Legha SS, 435, 437, 443, 907, 1085, 1197, 1411
Leichman LP, 1023
Leigh SA, 1125
Leyland-Jones B, 1455
Lele SB, 1433
LeMarbre PJ, 591, 1403
Leonard RCF, 1343
Le Prisé PY, 417
Le Rest R, 417
Lerner H, 1163
Lerner R, 1331
Lerner WA, 1383
Lessner HE, 929
Levi JA, 587, 1045
Levin M, 1511
Levin VA, 969
Levine HL, 1375
Levine P, 1157
Levine RM, 573
Levitan N, 1375
Lewin D, 1029
Leyva A, 543
Li D-J, 1149
Liao S, 1419
Licciardello JTW, 1375
Lichter AS, 695
Lindgren D, 1159
Lippman ME, 265, 573
Lipton A, 887
Lipton JM, 411
Lira-Puerto V, 669
Litterst CL, 999
Livingston RB, 1017
Locker GY, 1303
Lockner D, 1331
Loh K, 409
Lokey J, 1049
Long HJ, 1420
Lonnqvist B, 1331
Loo TL, 1293
Lopez JA, 1309
Lopez JJL, 1199
Loprinzi CL, 1195
Lowenbraun S, 423
Lu C, 711
Luch J, 1319
Luckert PH, 405
Ludwig CU, 367
Lukens J, 661

M

Ma HK, 775
Machover D, 881
MacIntyre JM, 1343
Mackie A, 651
MacKie RM, 1185
Madajewicz S, 913
Maekawa T, 527
Magill GB, 1053, 1415
Magrath IT, 599
Maguire HC, Jr, 207
Malden LT, 1045
Malspeis L, 1115
Manegold C, 1279
Mangioni C, 815
Manji M, 1015
Manning G, 1409
Marangos PJ, 859
Maraninchi D, 471

Marks M, 979
Marmonti L, 739
Maroun JA, 1121
Marsh JC, 615
Marsoni S, 77, 1455
Martin A, 417
Martin DS, 539, 1317
Martin JJ, 787
Martin-Jimenez M, 555
Martino S, 1057
Martoni A, 1391
Mastrangelo MJ, 207
Mathé G, 881
Mattsson W, 675
Maurer LH, 1403
Mauriac L, 921
Maxwell I, 1421
Mayol XF, 1199
McArdle C, 547
McBrien DCH, 445
McCarthy LE, 401
McCarthy WH, 1045
McClendon J, 1419
McCracken JD, 435, 1035, 1047, 1411
McCreadie S, 1269
McGrath L, 969
McGuffin RW, 317
McGuire WP, III, 568
McIntyre OR, 591, 685
McKelvey E, 409
McNitt K, 859
McVie JG, 607
Meinesz AF, 1471
Mellstedt H, 1331
Merante S, 1339
Merlano M, 1019
Mermillod B, 1079
Metter GE, 651
Meyers FJ, 1509
Micetich K, 989
Michaelson RA, 539
Miller S, 1303
Milton GW, 1045
Minna JD, 1439
Miser J, 695
Misset J-L, 881
Mitchell E, 1509
Mittelman A, 1319
Miura T, 1167
Moertel CG, 665, 1427
Momparler RL, 1143, 1483
Moon TE, 1125
Moore EC, 1293
Moore JV, 1005
Morain WD, 591
Morales-Canfield F, 669
Moran ME, 437
Morandi P, 1205
Morgan E, 661
Moriyama M, 1167
Morozumi M, 1357
Morrow GR, 1177
Morstyn G, 1439
Mortimer J, 1017
Morton DL, 723
Mouridsen HT, 683
Movassaghi N, 661
Muggia FM, 551, 669, 681, 931, 1383, 1511
Mulder NH, 779, 1471
Multhauf P, 651
Murphy WK, 437, 671
Murray N, 1299
Muscato JJ, 1097
Muscato MS, 1097
Myers CE, 1229
Myers JW, 927
Myers MB, 1387

N

Naporn A, 361
Natale RB, 427, 1411
Nechay BR, 1135
Neefe JR, 1049
Neff JR, 703
Neidhart JA, 1115
Nel CP, 891
Neldon SL, 1135
Nelson JA, 849
Nesbit ME, 703, 1157
Newman SB, 901
Nichols WC, 975, 1193
Niederle N, 791
Nielsen H, 1422
Nilsson B, 1331
Nissen NI, 1233
Nissenbaum M, 783
Nobile MT, 1285
Noble S, 413
Nooter K, 895
Nutik S, 969

O

Obrecht J-P, 563, 1079
O'Bryan R, 1411
O'Connell MJ, 551, 665, 803
O'Donnell JF, 591, 1403
O'Donnell MR, 559
O'Dwyer PJ, 959, 1215, 1455
Oettgen HF, 723
Oishi N, 435, 1025, 1411
Oldfield EH, 373
Oldham RK, 221
Oliveira Costa F, 1211
Olman EA, 1103
Omine M, 527
Omura GA, 929, 1517
Ooshima H, 1167
Opfell RW, 551
Osborne CK, 357
Osieka R, 799

Osman NM, 999
Osterlind K, 1289
Otteman LA, 1420
Ozarda AT, 1307
Ozols RF, 1229

P

Paavolainen M, 915
Pablo D, 1029
Pacilio G, 1310
Pajak TF, 685
Pallestrini E, 1019
Palva T, 915
Pamphilon D, 1033
Pan G-Y, 405
Pandya KJ, 1511
Panettiere FJ, 1023
Pannuti F, 1391
Panza N, 1310
Paoletti P, 1505
Parker RJ, 257
Parsons PG, 859, 1239
Pastmantier MW, 1397
Pastore G, 1051
Pater JL, 1121
Paterson AHG, 1421
Pauwels C, 749
Pavlovsky S, 581
Payne R, 173
Pedersen AG, 1289
Pedersen-Bjergaard J, 1233
Pegues DA, 1489
Peng YM, 1125
Peretz TY, 1191
Perez CA, 703
Perkins WE, 841
Perona G, 947
Perry A, 913
Perry DJ, 687
Perry MC, 923, 1097
Peterson C, 515
Petty WM, 809
Pfeffer MR, 1191
Pfeifle D, 493
Phillips TL, 291
Pianca C, 1051
Picket S, 1085
Piga A, 947
Pinedo HM, 505, 543
Pinkus GS, 1343
Pinnamaneni K, 1197
Plenderleith I, 1421
Plezia PM, 1493
Pocelinko R, 535
Pollard M, 405
Pomfret E, 1413
Poplack DG, 521
Porkka L, 655
Porzig KJ, 1509
Posada JG, 1215
Postmus PE, 1471
Poulin RF, 923
Poupon M-F, 749
Powers JF, 1247
Preisler HD, 1153, 1351
Presant CA, 531, 651, 813, 903
Prestifilippo J, 1029
Pritchard KI, 1421
Provisor A, 661
Pugh RP, 1035
Purvis JD, III, 1017

R

Rafla S, 1305
Ragaz J, 1015, 1421
Raghavan D, 1045
Rajeswari R, 727
Ramirez G, 1407
Ramsay NKC, 1157
Ramu A, 637
Rappaport D, 651
Ravry MJR, 1517
Raymond V, 1415
Raza A, 1351
Recher L, 1419
Redding TW, 281
Reimer RR, 435
Reitemeier RJ, 665
Renard J, 1055
Resser KJ, 969
Reynolds PM, 1045
Reynolds R, 983
Ribaud P, 881
Richards F, II, 923, 1397
Richardson AP, 340
Richman C, 1351
Richman SP, 1395
Richter MP, 303
Rifa J, 1199
Rioux E, 1467
Rivkin SE, 1411
Robertone AB, 1399
Roberts RA, 367
Roca E, 873
Romano C, 1051
Romano M, 643
Rørth M, 1179, 1422
Rosa B, 749
Rose DP, 719
Rosenbaum PR, 771
Rosenberg SA, 233, 1067
Rosenfeld CS, 659
Rosenthal DS, 1343
Ross WE, 521
Rosso R, 1019, 1285
Rozencweig M, 611, 1055
Rubens RD, 1447
Rubin J, 665, 1427
Rubio-Bazan R, 1199
Ruckdeschel JC, 1183, 1325

Ruddon RW, 859
Russo A, 1051
Rutledge FN, 1417, 1503

S

Sachs K, 1159
Sackmann MF, 581
Sallan SE, 411
Salmon SE, 117, 481
Salvaneschi L, 1339
Samulski TV, 309
Sandbach J, 357
Sandler S, 1163
Sangster G, 547
Santicky MJ, 447
Santoro A, 683
Santos GW, 711, 849
Saral R, 711
Sariban E, 599
Sather H, 661, 1269
Sato T, 1357
Savaraj N, 1307
Sawyer RC, 1317
Scarpati D, 1019
Schabel FM, Jr, 43
Schallier D, 787
Schally AV, 281
Schechter GP, 1439
Schein PS, 1049
Schell F, 805
Scher H, 561
Schertz G, 1049
Schiff S, 983
Schilsky RL, 1097
Schmidt CG, 791, 799
Schornagel JH, 543
Schottinger J, 1419
Schroeder M, 1279
Schroeder RL, 841
Schulman P, 979, 1305
Schutte J, 791
Schwartz CL, 1043
Schwarzenberg L, 881
Sebahoun G, 471
Seeber S, 791
Seltzer V, 1389
Sertoli MR, 1019, 1285
Sessa C, 815
Sethi VS, 933
Shah A, 1299
Shah MK, 1499
Shetty PA, 727
Shihabi Z, 933
Shinar E, 1169
Shiozaki H, 1167
Shiu W, 897
Showel J, 932, 1163
Shuin T, 1167
Sieber SM, 257
Siegenthaler P, 563, 1079
Silberstein PT, 1057
Silver HKB, 1093
Simon R, 185
Simonetti G, 607
Simonsson B, 1331
Singhakowinta A, 1057
Sironi M, 643
Skarin AT, 1343, 1413
Sketris IS, 446
Skipper HE, 43
Skosey C, 413
Sladek NE, 1247
Slater L, 1419
Slavik M, 809
Slayton RE, 1163, 1513
Sledge GW, Jr, 557
Sleijfer DT, 779, 1471
Sloane EM, 329
Smith CE, 647
Smith D, 547
Smith FP, 1049
Smith JC, 1219
Sobrero AF, 615
Somers R, 683
Sonneveld P, 895
Sordillo PP, 689, 1053, 1415
Spaulding M, 913
Spector AC, 1219
Sperandio P, 1205
Speyer JL, 1229, 1383
Speyer JS, 681
Spitzer G, 671, 805
Spitzer M, 1389
Spreafico F, 643
Spurr CL, 933
Stalfelt A-M, 1331
Staquet M, 611
Stark R, 1383
Steinhorn SC, 953
Steller MA, 257
Stephens RL, 409, 435, 443, 1025, 1411
Sternberg CN, 1053
Steward WP, 897
Stewart DJ, 437, 1121
Stiff P, 1303
Stolbach LL, 1325
Stolfi RL, 1317
Stoller RG, 447
Strander H, 1331
Struck RF, 765
Stuckey WJ, 435, 1025
Sulkes A, 1191
Summers JL, 1027
Surwit EA, 443, 1493
Suzuki T, 527
Svarch E, 581
Svedmyr E, 1331
Sweet DL, 901, 1303

T

Takasugi BJ, 1399

Talley RW, 435
Tan CTC, 441
Tanghetti B, 1505
Tannir N, 805, 1039
Tapiero H, 881
Tattersall MHN, 1045
Taylor B, 1163
Taylor SG, IV, 877, 919, 932
ten Bokkel Huinink WW, 607
Telander R, 661
Terblanche APS, 1311
Thatcher N, 897
Thomas BS, 1447
Thomas D, 683
Thomas PJ, 1173
Thomas PRM, 703
Thongprasert S, 1301
Tigges F-J, 1279
Tilchen EJ, 1023
Tipping SJ, 687
Todeschini G, 947
Tomasi L, 1391
Tong M, 487
Tormey DC, 1407, 1515
Torti FM, 1509
Toujas L, 417
Tranum BL, 443
Tritchler D, 1183, 1297
Trump DL, 719, 925, 1195
Tryka AF, 759
Tseng MH, 1319
Tsiatis AA, 551
Tutschka PJ, 711
Tyson LB, 163

U

Umezawa H, 137
Umsawasdi T, 671
Uozumi J, 1367

V

Valdivieso M, 671
Valle M, 499
Van Belle S, 787
van der Vijgh WJF, 505
Van Echo DA, 535, 687, 1103
VanHelvoirt A, 563
van Oosterom AT, 683
Vardiman JW, 901
Vaughn CB, 409
Vecchi A, 643
Vendrik C, 683
Vercellotti GM, 1057
Vergara B, 581
Vermorken JB, 505, 1055
Vestnys P, 969
Vinciguerra V, 979
Vitols S, 515
Vogl SE, 559, 1183, 1273, 1389, 1497
Volberding P, 1509
Von Hoff DD, 357, 557, 733, 919, 927
Vriesendorp R, 779, 1471

W

Wadman B, 1331
Wagener T, 683
Waller HD, 1283
Wang DY, 1447
Ward K, 817
Wassenaar HA, 895
Wasserman TH, 291
Weaving A, 783
Wedelin C, 1331
Weible KH, 1283
Weick JK, 963
Weiler CB, 807
Weinberg V, 923
Weiner R, 1351
Weinstein JN, 127, 257
Weintraub H, 637
Weiselberg L, 979
Weiss RB, 959
Weissman CH, 1325
Wernz JC, 669, 681, 931, 1383
Westling H, 867
Whang-Peng J, 989
Wharton JT, 1417, 1503
Wheeler RH, 427
Wheelock JB, 1387
Whitacre MY, 859, 1103
White H, 661
Whitehead RP, 771
Wiernik PH, 535, 859
Wilkinson PM, 897
Willemse PHB, 779
Wilson CB, 969
Wilson L, 1185
Winton L, 1351
Wirtschafter JD, 565
Witherspoon RP, 435
Witte RS, 1407
Wittes RE, 77, 329, 561, 679, 1301
Woll J, 1183, 1351
Wong LC, 775
Woodard DA, 647
Woodburn RT, 818
Woodcock TM, 1395
Woods RL, 1045
Woods WG, 1157
Woolley PV, 1049

Y

Yap H-Y, 1039, 1197
Yoshino H, 1357

Young B, 361
Young CW, 539
Yu K-P, 983

Z

Zaharko DS, 1255, 1475
Zeese JA, 565
Zeigler P, 913
Ziegler JL, 419, 793
Zubrod CG, 9
Zwelling LA, 989